Pro-beneficial agent compound having a complex ring moiety

Abstract

Probenefit agent compounds having a heterocyclic moiety containing a benefit agent fragment derived from a benefit agent, such as a perfume raw material containing an aldehyde or ketone moiety. The probenefit agent compounds may be derived from modified amino acids. Related treatment compositions, premix compositions, precursor compounds, and methods of making and using such materials and compositions.

Description

Technical Field

[0001] The present disclosure relates to certain pro-beneficial agent compounds having a heterocyclic moiety, related precursor compounds, related premixes, related treatment compositions, and methods of making and using such materials and compositions. The pro-beneficial agent compounds can be derived from hydrophobic modified amino acids.

Background Art

[0002] Manufacturers of treatment compositions are constantly seeking ways to improve the delivery efficiency and / or performance benefits associated with certain beneficial agents. The use of pro-beneficial agent compounds, where the beneficial agent moiety is attached to a carrier molecule by a cleavable or hydrolyzable bond and then released when the bond is broken, can be a useful strategy. For example, certain amine compounds can form the basis of pro-fragrance or pro-aroma technologies. However, there is still room for improvement with respect to stability and / or adhesion profiles. An additional area of need is the development of pro-fragrances that substantially do not contain a chromophore when mixed with a beneficial agent having a conjugated π-system.

[0003] Furthermore, consumers may desire materials related to a desired environmental profile or sustainability profile.

Summary of the Invention

Problems to be Solved by the Invention

[0004] There is a need for pro-beneficial agent compounds that provide improved delivery, release, and / or stability profiles, and for treatment compositions containing such compounds. There is also a need for methods of making and using such treatment compositions.

Means for Solving the Problems

[0005] The present disclosure relates to pro-beneficial agent compounds comprising a heterocyclic moiety formed in part from a beneficial agent fragment.

[0006] For example, the present disclosure relates to a pro-beneficial agent compound, the compound having a carbon-containing core, the carbon-containing core comprising a carbon skeleton, one or more side groups, a nitrogen atom, and a carbonyl group, the carbonyl group being part of a carbonyl-containing moiety selected from an ester moiety, an amide moiety, or a thioester moiety, the carbonyl-containing moiety comprising a first heteroatom bonded to the carbon of the carbonyl group, the first heteroatom being selected from oxygen, nitrogen, or sulfur, the carbonyl-containing moiety further comprising a first monovalent moiety bonded to the first heteroatom, the first monovalent moiety being an organic group comprising 1 to 34 chain atoms, a carbon-containing core, and a beneficial agent fragment, wherein the carbon atoms of the beneficial agent fragment, the nitrogen of the carbon-containing core, and a second heteroatom are part of a heterocyclic moiety, the second heteroatom being selected from oxygen, nitrogen, and sulfur, the second heteroatom being part of the heterocyclic moiety, the carbon atoms of the beneficial agent fragment being bonded to the nitrogen and the second heteroatom, the beneficial agent fragment being derived from a beneficial agent comprising an aldehyde moiety, a ketone moiety, or a combination thereof, the heterocyclic moiety optionally further comprising a second monovalent moiety that is an organic group comprising 1 to 34 chain atoms, preferably carbon atoms, a beneficial agent fragment, wherein at least one of (a) at least one of the first monovalent moiety and, if present, the second monovalent moiety comprises at least 5, preferably at least 8, chain atoms, preferably carbon atoms, and / or (b) the second monovalent moiety is present and the sum of the number of chain atoms, preferably carbon chain atoms, in the first monovalent moiety and the second monovalent moiety is at least 8, applies. The pro-beneficial agent compound is preferably derived from a modified amino acid.

[0007] The present disclosure also relates to a treatment composition comprising an auxiliary component and a pro-beneficial agent compound as described above.

[0008] The present disclosure also relates to a pro-beneficial agent precursor compound. The precursor compound may be characterized by the following structure,

[0009]

Chemical formula

[0010] The present disclosure also relates to a premix composition comprising the above-mentioned pro-beneficial agent precursor compound and a beneficial agent, wherein the beneficial agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof. The pro-beneficial agent precursor compound and the beneficial agent may optionally react to form the pro-beneficial agent precursor compound described herein. In the premix composition, the total weight percentage of the pro-beneficial agent precursor compound, the beneficial agent, and, if present, the pro-beneficial agent compound (if present) may be from about 10 wt% to about 100 wt% of the premix composition, preferably from about 25 wt% to about 100 wt%, more preferably from about 50 wt% to about 100 wt%, and even more preferably from about 75 wt% to about 100 wt%.

[0011] The present disclosure relates to a method for preparing a treatment composition described herein. The method may include (a) mixing a pro-beneficial agent compound, preferably with an auxiliary component that is part of the base composition, (b) combining the above-mentioned premix composition, preferably with an auxiliary component that is part of the base composition, and (c) mixing the pro-beneficial agent precursor compound, the beneficial agent, and the auxiliary component, preferably wherein the auxiliary component is part of the base composition and the pro-beneficial agent precursor compound and the beneficial agent are added to the base composition as separate inputs, and may include at least one of the above.

[0012] The present disclosure also relates to a method for treating a surface, the method including contacting the surface with a treatment composition according to the present disclosure, optionally in the presence of water.

Brief Description of the Drawings

[0013] The drawings herein are illustrative in nature and are not intended to be limiting.

Figure 1

Modes for Carrying Out the Invention

[0014] The present disclosure relates to pro-beneficial agent compounds that can be derived from modified amino acids. The compounds may include fragments or residues of beneficial agents, such as fragrance ingredients or antibacterial agents, that contain an aldehyde or ketone moiety. In the pro-beneficial agent compounds of the present disclosure, the beneficial agent fragment or residue is bonded to the nitrogen atom of the modified amino acid and another heteroatom to form a heterocyclic moiety together with other atoms. Without being bound by theory, it is believed that when the bond connecting the beneficial agent fragment to the nitrogen atom and the second heteroatom is cleaved, the beneficial agent is released. In addition to providing a beneficial release profile, the properties of the heterocyclic moiety tend to provide improved stability, particularly improved color stability, in treatment compositions containing such compounds, compared to other nitrogen-containing pro-beneficial agent compounds.

[0015] Furthermore, the modified amino acid includes one or more monovalent moieties that are organic groups that increase the relative hydrophobicity of the compound. For example, the first monovalent organic moiety is bonded to the acid terminus of the amino acid, thereby forming a carbonyl-containing group that can be selected from an ester group, an amide group, or a thioester group. Additionally or alternatively, a second monovalent organic group may be bonded to the heterocyclic moiety, separate from any organic moiety that forms part of the beneficial agent fragment. The hydrophobicity imparted by the organic group(s) is believed to improve the delivery and / or attachment of the pro-beneficial agent compound to the intended target surface or article.

[0016] Such pro-beneficial agent compounds, related treatment compositions, and related methods are described in more detail below.

[0017] As used herein, the articles "a" and "an" when used in the claims are understood to mean one or more of what is claimed or described. As used herein, the terms "include", "includes", and "including" are meant to be non-limiting. The compositions of the present disclosure can comprise, consist essentially of, or consist of the components of the present disclosure.

[0018] In this specification, the terms "substantially free of" or "substantially free from" may be used. This means that the indicated material is present in minimal amounts and is not intentionally added to the composition to form part of the composition, or preferably, is not present at analytically detectable levels. It means that the composition includes the indicated material only as an impurity in one of the other materials that are intentionally included. The indicated material, if present, may be present at a level of less than 1% by weight, or less than 0.1% by weight, or less than 0.01% by weight, or even 0% by weight of the composition.

[0019] As used herein, the phrase "fabric care composition" includes compositions and formulations designed to treat fabrics. Such compositions include laundry washing compositions and detergents, fabric softening compositions, fabric strengthening compositions, fabric deodorizing compositions, pre-wash detergents, pre-wash treatment agents, laundry additives, spray products, dry cleaning agents or compositions, post-rinse additives, cleaning additives, post-rinse fabric treatment agents, ironing aids, unit dose formulations, delayed delivery formulations, detergents contained on or in porous substrates or non-woven sheets, and other suitable forms that may be apparent to those skilled in the art in view of the teachings herein, but are not limited thereto. Such compositions can be used as pre-wash treatment agents, post-wash treatment agents, or added during the rinse or wash cycle of a laundry operation.

[0020] As used herein, the phrase "chain atoms" means the sum of all atoms in the indicated group or moiety, excluding hydrogen atoms. The chain atoms may be in a straight-chain configuration, a branched-chain configuration, and / or a cyclic configuration.

[0021] Unless otherwise noted, all levels of components or compositions are with respect to the active portion of such components or compositions, and impurities that may be present in commercial sources of such components or compositions, such as residual solvents or by-products, are excluded.

[0022] All temperatures in this specification are in degrees Celsius (°C) unless otherwise indicated. Unless otherwise stated, all measurements in this specification are carried out at 20 °C and atmospheric pressure.

[0023] In all embodiments of the present disclosure, all percentages are relative to the weight of the total composition unless otherwise specified. Unless otherwise stated, all ratios are by weight.

[0024] All upper numerical limits given throughout this specification are to be understood to include all lower numerical limits as if such lower numerical limits were expressly recited herein. All lower numerical limits shown throughout this specification are to include all higher numerical limitations as if such higher numerical limitations were expressly recited herein. All numerical ranges given throughout this specification are to include every narrower numerical range that falls within such broader numerical range as if such narrower numerical ranges were all expressly recited herein.

[0025] Pro-beneficial agent compound The present disclosure relates to pro-beneficial agent compounds. A pro-beneficial agent compound contains a fragment (e.g., a residue) of a beneficial agent. The beneficial agent from which the fragment is obtained contains an oxygen-containing moiety, i.e., an aldehyde moiety or a ketone moiety.

[0026] A beneficial agent fragment, which may be a first beneficial agent fragment, is bonded to a nitrogen atom of a carrier molecule by a carbon / nitrogen linking bond. As will be described in more detail below, the beneficial agent is also bonded to another heteroatom. The nitrogen, the carbon of the beneficial agent fragment, and the second heteroatom form part of a heterocyclic moiety.

[0027] When the bond that links the beneficial agent fragment to the heterocycle is cleaved, the beneficial agent is released. The release of the beneficial agent may be caused by any suitable mechanism such as water or heat, preferably the presence of water, especially when the linking bond is, for example, an N-C-O bond.

[0028] The beneficial agent compounds of the present disclosure can be derived from modified amino acids. Since protein - constituent amino acids are prone to be naturally occurring, such compounds can be attractive and preferable starting materials for environmental or sustainability reasons. For most naturally occurring amino acids, the stereogenic carbon at the α - position relative to the amino group has the L - configuration. D - amino acids are occasionally found in nature. Either L - amino acids or D - amino acids, as well as mixtures, can be used, but due to economic factors, the more abundant L - amino acids may be preferred. In this regard, biosynthetic amino acids may be preferred.

[0029] The starting amino acid can be modified by reacting the carboxylic acid group of the amino acid with (a) an alcohol of an organic group via an esterification reaction, (b) an amine of an organic group via an amidation reaction, or (c) a thiol group of an organic group via a thioesterification reaction. Such reactions can result in ester, amide, or thioester linking groups, respectively. Such linking groups, each of which is a type of carbonyl - containing partial group, may be preferred over other linking groups in order to facilitate the reaction. Compounds formed using such carbonyl - containing moieties may be even more preferred for environmental reasons because these types of groups can decompose (e.g., hydrolyze) over time and / or in the presence of water to return the core material to, for example, a common amino acid.

[0030] The present disclosure relates to a pro-beneficial agent compound, which compound has a carbon-containing core, the core comprising a carbon skeleton, one or more side groups, a nitrogen atom, and a carbonyl group, the carbonyl group being part of a carbonyl-containing moiety selected from an ester moiety, an amide moiety, or a thioester moiety, the carbonyl-containing moiety comprising a first heteroatom bonded to the carbon of the carbonyl group, the first heteroatom being selected from oxygen, nitrogen, or sulfur, the carbonyl-containing moiety further comprising a first monovalent moiety bonded to the first heteroatom, the first monovalent moiety being an organic group comprising from 1 to 34 chain atoms, a beneficial agent fragment, wherein the carbon atoms of the beneficial agent fragment, the nitrogen of the carbon-containing core, and a second heteroatom are part of a heterocyclic moiety, the second heteroatom being selected from oxygen, nitrogen, and sulfur, the second heteroatom not being part of a side group of the core, the carbon atoms of the beneficial agent fragment being bonded to the nitrogen and the second heteroatom, the beneficial agent fragment being derived from a beneficial agent, the beneficial agent comprising an aldehyde moiety, a ketone moiety, or a combination thereof, the heterocyclic moiety optionally comprising a second monovalent moiety (not directly bonded to the carbon atoms of the beneficial agent) which is an organic group comprising from 1 to 34 chain atoms, preferably carbon atoms, wherein at least one of (a) the first monovalent moiety, and when present, the second monovalent moiety comprises at least 5, preferably at least 8 chain atoms, preferably carbon atoms, and / or (b) the second monovalent moiety is present and the total number of chain atoms, preferably carbon chain atoms, in the first and second monovalent moieties is at least 8.

[0031] The carbon-containing core comprises a carbon skeleton. The carbon skeleton is understood not to include the carbon of the carbonyl-containing moiety or, when present, the side group(s). The carbon skeleton can comprise from 1 to 6 carbon atoms, preferably from 1 to 3 carbon atoms, more preferably 1 carbon atom. For reasons of mass efficiency, a relatively small number of carbon atoms may be preferred. In particular, a skeleton comprising only 1 carbon atom may be preferred since such structures are indicative of the proteinogenic amino acids that occur naturally.

[0032] The carbon-containing core can be derived from an amino acid. Preferably, the core is derived from the protein constituent amino acids. In particular, naturally-derived or biosynthetic amino acids may be preferred. Such materials may be preferred for environmental / sustainability reasons and because they tend to be readily available at reasonable costs.

[0033] At least one side group can be selected from hydrogen or a suitable organic group, preferably hydrogen or an organic group having 1 to about 20 chain atoms, preferably carbon atoms. At least one side group may contain one or more functional groups such as a carboxyl group, an amine group, a thiol group, or a hydroxyl group. At least one side group may be linear or branched. At least one side group may contain an aryl ring. The compound may preferably contain only one non-hydrogen side group (e.g., only one organic group). The compound may contain two or more non-hydrogen side groups. At least one side group preferably contains the side group of a protein constituent amino acid. The carbon-containing core may contain at least one side group that is hydrogen and at least one side group that is an organic group. For example, if the core is based on or derived from glycine, all side groups may be hydrogen.

[0034] The side group may have the structure of the side group of a protein constituent amino acid or a derivative thereof, preferably selected from the group consisting of alanine, glycine, valine, phenylalanine, leucine, isoleucine, derivatives thereof, or combinations thereof, more preferably alanine, glycine, valine, phenylalanine, derivatives thereof, or combinations thereof, even more preferably alanine, glycine, derivatives thereof, or combinations thereof. The derivative may include a substitution containing a beneficial agent fragment bonded to the side group derivative.

[0035] At least one side group can include members having a structure selected from the following group, where "#" represents the location where the side group is bonded to the carbon atom of the carbon-containing core.

[0036]

Table 1

[0037] When the carbon-containing core has a side group having a structure that is a side group of a protein constituent acid, preferably including a side group selected from the above table, the remaining side groups may preferably be hydrogen.

[0038] The carbon-containing core (e.g., the parent amino acid) may preferably contain a relatively hydrophobic side group, for example, one that does not contain a hydrophilic functional group such as a carboxy group. The relatively hydrophobic side group is considered to facilitate the attachment of the pro-beneficial agent compound to the target surface, particularly when the compound is delivered in an aqueous solution such as a laundry detergent solution.

[0039] The protein constituent amino acid from which the carbon-containing core is derived may be selected from the group consisting of alanine, glycine, valine, phenylalanine, leucine, isoleucine, or combinations thereof, more preferably alanine, glycine, valine, phenylalanine, or combinations thereof, even more preferably alanine, glycine, or combinations thereof. Such pro-beneficial agent compounds derived from these amino acids have been found to be particularly effective for delivering beneficial agents, particularly fragrance raw materials, more specifically in laundry applications.

[0040] The pro-beneficial agent compound of the present disclosure includes a first monovalent moiety bonded to the core at a carbonyl-containing moiety. The first monovalent moiety is an organic group containing 1 to 34 chain atoms, preferably carbon chain atoms.

[0041] The pro-beneficial agent compound of the present disclosure may optionally include a second monovalent moiety that is part of a heterocyclic moiety. As used herein, the second monovalent moiety is understood not to be part of a beneficial agent fragment and / or not directly bonded to a carbon atom of the beneficial agent. The second monovalent moiety may be an organic group containing 1 to 34 chain atoms, preferably carbon atoms.

[0042] Although not bound by theory, by modifying the carbon-containing core with the first and optionally the second monovalent moieties as described above, the resulting compounds become relatively hydrophobic compared to the delivery compounds having unmodified cores, and thereby, the adhesion and / or performance benefits of the resulting pro-beneficial agent compounds are thought to be promoted. Thus, it may be important to select appropriate monovalent moieties such that a desired degree of hydrophobicity is imparted to the compound.

[0043] For example, with respect to the pro-beneficial agent compounds of the present disclosure, at least one of the following may apply: (a) at least one of the first monovalent moiety and, if present, the second monovalent moiety contains at least 5, preferably at least 8 chain atoms, preferably carbon atoms, and / or (b) the second monovalent moiety is present and the total number of chain atoms, preferably carbon chain atoms, in the first monovalent moiety and the second monovalent moiety is at least 8.

[0044] The first and / or second monovalent moieties may be relatively hydrophobic, in which case it may be referred to as a "hydrophobic substance". As used in this context, "hydrophobic" means describing an organic group having a logP of at least 1.3, where logP is determined for the parent alcohol of the organic group regardless of whether the organic group is derived from an alcohol, amine, thiol, or oxirane. For example, if the first monovalent moiety is a hydrophobic substance that is a straight-chain group having 8 carbons and is bonded to the first heteroatom of the carbonyl-containing moiety at the terminal position of the hydrophobic substance, logP is determined according to the logP value of 1-octanol (in this case, logP = about 3.0) regardless of whether the hydrophobic group is bonded to the core via an ester bond, an amide bond, or a thioester bond (see Table A below). The hydrophobic moiety may be characterized by a logP of at least 1.3, or about 2.8 to about 10.8, or about 3.0 to about 7.8, or about 5.0 to about 6.9. The method for determining logP is found in the section on test methods below.

[0045] [Table 2] α The logP of each individual substance is determined using the Consensus logP Computational Model, version 14.5 (Linux®), available from Advanced Chemistry Development Inc. (ACD / Labs), Toronto, Canada.

[0046] As described above, the first monovalent moiety can be attached to the carbon-containing core by a carbonyl-containing moiety selected from an ester moiety, an amide moiety, or a thioester moiety. Such a carbonyl-containing moiety can be formed by reacting the carboxylic acid terminus of the core amino acid with a suitable functional group of a suitable organic group (e.g., an alcohol, an amine, or a thiol). The carbonyl-containing moiety that attaches the first monovalent moiety to the core may preferably be an ester moiety, for example, due to the low cost of the alcohol precursor or the favorable environmental profile of the resulting ester.

[0047] As noted above, certain minimal chain atoms, preferably carbon chain atoms, are useful for increasing the relative hydrophobicity of the group and thus the resulting compound may serve to facilitate attachment or increased performance. The first and / or second monovalent moieties may be organic groups containing from about 8 to about 18 chain atoms, more preferably from about 8 to about 14 chain atoms, and even more preferably most or all of the chain atoms are carbon atoms.

[0048] When the beneficial agent fragment is derived from a fragrance raw material, a relatively high hydrophobicity may be preferred for attachment or performance reasons. For example, when the beneficial agent released is a fragrance raw material, at least one of the first monovalent moiety and the second monovalent moiety may be an organic group containing from about 8 to about 18, preferably from about 10 to about 18, more preferably from about 12 to about 18, and even more preferably from about 12 to about 16 chain atoms, and preferably most or all of the chain atoms are carbon atoms.

[0049] When the beneficial agent fragment is derived from an antibacterial agent, relatively low hydrophobicity may be preferred for performance reasons. For example, when the released beneficial agent is an antibacterial agent, the organic group may contain about 6 to about 14, preferably about 6 to about 12, preferably about 8 to about 12, more preferably about 8 to about 10 chain atoms, and preferably the chain atoms are carbon atoms.

[0050] The hydrophobic moiety may be optionally substituted, but such substitution is preferably selected to maintain the hydrophobicity of the organic group. For example, the organic group may contain relatively hydrophobic substitutions. Additionally or alternatively, the organic group may contain hydrophilic substitutions, but they are preferably kept to a minimum and / or the number of chain atoms is appropriately selected to offset part of the hydrophilicity of the substitution. For example, when the organic group contains a hydroxyl substitution, it may be preferred for the organic group to contain at least 10, preferably at least 12 carbon atoms.

[0051] The first and / or second monovalent moieties may be unsubstituted organic groups, unbranched organic groups, or combinations thereof. Preferably, the first and / or second monovalent moieties are both unsubstituted and unbranched. Such moieties may be preferred due to convenient availability, performance profiles, and relatively low environmental impact. Suitable moieties may be derived from n-octanol, n-decanol, n-dodecanol, etc.

[0052] The first and / or second monovalent moieties may be derived from a mixture of feedstock substances such as fatty alcohols. The feedstock substances may include substances having variable chain lengths. In such cases, the chain lengths described herein for the first and second moieties are understood to be the weight average chain lengths.

[0053] Additionally or alternatively, the feedstock materials can include some linear and some branched materials. Thus, when reacting the feedstock to form the precursors or pro-beneficial agent compounds of the present disclosure, some materials include linear monovalent moieties and other materials include branched monovalent moieties. Such mixtures are contemplated in the present disclosure.

[0054] In addition to the beneficial agent to which the first and / or second monovalent moieties are attached as fragments to the nitrogen atom of the heterocycle and the second heteroatom, the second fragment of the second beneficial agent that can ultimately be released from the pro-beneficial agent compound may be included, which may be referred to as the first beneficial agent. Such a configuration may be preferred for reasons of packing efficiency. The two fragments can be attached to the compound and released from the compound. Such a configuration may also be preferred to enable different beneficial agents to be released from the same compound.

[0055] For example, the second beneficial agent fragment may have a uniqueness different from that of the beneficial agent fragment (e.g., the first beneficial agent fragment) that is part of the heterocyclic moiety. Both fragments may be beneficial agents of the same category (e.g., both are derived from fragrance raw materials), but they may have different uniqueness. Preferably, the first and second beneficial agents include different functional groups. For example, the first beneficial agent may include an aldehyde or ketone moiety, and the second beneficial agent may include a functional group that is not an aldehyde or ketone moiety. The second beneficial agent may include a functional group that is an alcohol, amine, thiol, or a combination thereof.

[0056] Preferably, the second beneficial agent includes a functional group that is an alcohol group. Such alcohol-containing materials may be preferred to facilitate the reaction with the carboxylic acid of the amino acid core (e.g., thereby forming an ester). Such substances may also be preferred to provide a wider range of substances released from the pro-beneficial agent compound (e.g., an aldehyde or ketone-containing beneficial agent combined with an alcohol-containing beneficial agent).

[0057] The first and / or second monovalent moiety may be replaced with a fragment of a second beneficial agent. The first and / or second monovalent moiety may be (in its entirety) a fragment of a second beneficial agent.

[0058] The second beneficial agent may be a fragrance raw material, preferably an alcohol-containing fragrance raw material. In such a case, it is also preferable that the first beneficial agent (e.g., the parent substance of the fragment bonded to the core nitrogen atom) is also a fragrance raw material, which enables more efficient fragrance delivery and / or a more complex olfactory experience.

[0059] For environmental reasons, the first and / or second monovalent moiety may preferably be derived from natural-derived materials or raw materials, particularly when the carbon-containing core is derived from natural amino acids. Suitable natural-derived materials or feedstocks can include natural fats and / or oils.

[0060] The pro-beneficial agent compound may be characterized by the structure according to formula I,

[0061]

Chemical formula

[0062] The pro-beneficial agent compound may be characterized by the structure according to formula II,

[0063]

Chemical formula

[0064] To illustrate the above, Figure 1 shows an annotated structure of a pro-beneficial agent compound according to the present disclosure, for example, a compound according to Formula II. The pro-beneficial agent compound 1 includes a carbon-containing core 2. The core 2 includes one or more carbon atoms (depending on the value of the subscript m) bonded to the side groups R 1 and R 2 These carbon atoms (not including R 1 or R 2 ) form the carbon skeleton of the compound 1. The core 2 also includes a carbonyl group 3. The carbonyl group 3 is part of a carbonyl-containing moiety 4, which can be an ester, an amide, or a thioester depending on which type of first heteroatom (-G-) is present and to which the first monovalent moiety -Q is bonded. The compound 1 also includes a heterocyclic moiety 5 that partially contains a beneficial agent fragment 6. Although not explicitly shown in Figure 1, the compound 1 can include a second monovalent moiety bonded to the heterocyclic moiety 5. The second monovalent moiety is typically bonded to a -J group.

[0065] In Formula II, G and G' are -O-, -S-, or -N(R 3)-and may preferably be -O-. Esters obtained when G is -O- may be preferred for environmental reasons and for the convenient availability of alcohol-based feedstock materials. For clarity, the -C(O)G moiety of Formula II represents the carbonyl-containing moiety of the carbon-containing core attached to the first monovalent moiety (Q). G' may preferably also be -O- for the convenient availability and reactivity of feedstock materials such as oxirane.

[0066] In Formula II, G and / or G' may be selected from -N(R 3 )-, where R 3 is selected from -H or a monovalent moiety having a molecular weight of about 15 to about 142 Da, preferably R 3 is selected from -H or a monovalent moiety having a molecular weight of about 15 to about 30 Da, more preferably R 3 is -H. A relatively small R 3 moiety, especially hydrogen, may be preferred when forming an amide bond, for example, for favorable reactions and feedstock availability.

[0067] In Formula I or II, Q can contain 1 to 34 chain atoms, preferably about 1 to about 18 chain atoms, more preferably about 2 to about 12 chain atoms, and most preferably, most or preferably all of the chain atoms are carbon atoms. The Q group may be unsubstituted, unbranched, or a combination thereof, preferably a combination thereof.

[0068] R 6 When the R 6 group is present as part of the J moiety, the R 6 group may be an organic group that functions as a second monovalent moiety that is part of a heterocyclic moiety. The R

[0069] As described above, the first monovalent moiety (e.g., Q), and optionally the second monovalent moiety (e.g., R 6When present, it is preferably selected to provide sufficient hydrophobicity for efficient adhesion and / or performance benefits. (a) Q and R 6 When at least one of (a) and / or R 6 is present, it contains at least 5, preferably at least 8, more preferably at least 10, even more preferably at least 12 chain atoms, preferably carbon atoms, and (b) and / or R 6 is present, and at least one of the total number of chain atoms, preferably carbon chain atoms, in Q and R

[0070] is at least 8, preferably at least 10, more preferably at least 12, as long as sufficient hydrophobicity is provided, the Q group and / or R 6 group may be substituted with, for example, oxygen. For example, the Q group and / or R 6 group may contain an ether moiety, a hydroxyl moiety, or a combination thereof.

[0071] For example, the Q group (e.g., the first monovalent moiety) and / or R 6 group (e.g., the second monovalent moiety), preferably the Q group, may preferably contain one or more alkoxy groups selected from ethoxy, propoxy, or butoxy groups, or combinations thereof. For example, the Q group and / or R 6 group may have the empirical formula -(C n H 2n O y ) x H, where each subscript x is independently selected from 1 to 12, preferably x is from 4 to 10, more preferably x is from 5 to 7, each subscript n is independently selected from 1 to 4, preferably n is 1 or 2, and each subscript y is from 0 to 1, preferably y is 1 when the group contains an alkoxy group.

[0072] The Q group (e.g., the first monovalent moiety) and / or R 6 group (e.g., the second monovalent moiety), preferably the Q group, may contain an -OH group, and in particular the Q group / first monovalent moiety is derived from a diol.

[0073] For reasons of mass efficiency, it may be preferable for one of the Q group and the R 6 group to be relatively long and the other to be relatively short. For example, Q may contain at least 8 chain atoms, and R 6 group, if present, contains no more than 4 chain atoms, preferably R 6 group, if present, contains no more than 2 chain atoms, and more preferably all R 6 groups, if present, are hydrogen. At least one R 6 contains at least 8 chain atoms, the Q group contains 1 to 4 chain atoms, and preferably the Q group can contain 1 to 2 chain atoms.

[0074] The Q group may contain a second fragment of the second beneficial agent, preferably a second perfume raw material, more preferably an alcohol-containing second perfume raw material. In such a case, G can be -O-. When such a material is present, other materials containing a carbon-containing core and a first monovalent group but not containing a first beneficial agent fragment bonded to the nitrogen of the carbon-containing core may also be present.

[0075] In formula II, R 1 and R 2 are independently selected from -H or a monovalent moiety having a molecular weight of about 15 to about 1000 Da, preferably independently selected from -H or a monovalent moiety having a molecular weight of about 15 to about 507 Da, and more preferably independently selected from -H or a monovalent moiety having a molecular weight of about 15 to about 142 Da. R 1 and / or R 2 is a side group of the carbon-containing core. R 1 and R 2 At least one of, preferably at least one R 1 is preferably such that when R 2 is hydrogen (-H) and m = 1, it is a monovalent moiety having the structure of the side chain of a proteinogenic amino acid. R 1 and R 2At least one of them can contain a beneficial agent fragment, and such a configuration may be preferable for reasons of mass efficiency in that one carrier contains two fragments (one as part of the heterocyclic moiety and one on the side chain).

[0076] At least one R 1 or R 2 groups can have the structure of the side chains of the protein - constituting amino acids, preferably the side chains of alanine, glycine, valine, phenylalanine, leucine, isoleucine, or combinations thereof, more preferably the side chains of alanine, glycine, valine, phenylalanine, or combinations thereof, even more preferably the side chains of alanine, glycine, or combinations thereof, selected from the group consisting of the side chains of the protein - constituting amino acids.

[0077] In formula II, the subscript m is from 1 to 6, preferably m is from 1 to 3, more preferably m is 1. When the subscript m is 1, the carbon - containing core may be derived from a naturally - occurring or biosynthetic protein - constituting amino acid, which may be preferable for environmental reasons.

[0078] In formula I or II, the Z group represents a beneficial agent fragment. Preferably, the Z moiety contains about 4 to about 34 carbon atoms. The Z moiety is preferably a fragment of a fragrance raw material. The beneficial agent and its fragments will be described in more detail below.

[0079] The Z group representing the beneficial agent fragment can have the following structure.

[0080]

Chemical formula

[0081] When the Z group is a fragment of an aldehyde-containing beneficial agent, R 5 is hydrogen. When the Z group is a fragment of a ketone-containing beneficial agent, R 5 is an organic moiety. Such fragments may be derived from the beneficial agent of the formula R 4 -C(O)-R 5 and / or may bring about the release of the beneficial agent. The beneficial agent and its fragments may be characterized by a relatively low molecular weight, for example, from about 100 g / mol to about 1000 g / mol, preferably from about 100 g / mol to about 500 g / mol, and the R 4 and R 5 groups may be selected accordingly.

[0082] In formula I, the A group may be characterized by the following structure, formula III,

[0083]

Chemical formula

[0084] The pro-beneficial agent compound may be characterized by a structure according to formula IV,

[0085]

Chemical formula

[0086] In such a configuration, the pro-beneficial agent compound is considered to provide favorable performance benefits and have a beneficial environmental profile.

[0087] The pro-beneficial agent compound may be characterized by a structure according to Formula V,[[]]

[0088]

Chemical formula

[0089] The pro-beneficial agent compound may be characterized by a structure according to Formula II, wherein m = 1, R 1 is a side group of a proteinogenic amino acid, and R 2 is -H. This embodiment may be preferred because it can be based on a naturally occurring amino acid core. In such cases, G = -O- may be more preferred because the resulting ester may be environmentally preferred.

[0090] The pro-beneficial agent compound may be characterized by a structure according to Formula II, wherein Q is an organic group containing about 8 to about 18 chain atoms, preferably most or even all of the chain atoms are carbon atoms. G = -O-, m = 1, R 1 is a side group of a proteinogenic amino acid, R 2 is -H, d = 2, and each J = C(R 6) It is 2, and preferably, R 6 is hydrogen, G’ = -O-, and Z is a fragrance raw material, preferably a fragment of a fragrance raw material containing an aldehyde moiety. In such a configuration, the pro-benefit agent compound is considered to provide favorable performance benefits and have a beneficial environmental profile.

[0091] The pro-benefit agent may further include a second benefit agent fragment. Preferably, the pro-benefit agent compound is characterized by the structure according to Formula II, and the second benefit agent fragment is Q, R 1 , R 2 , or R 6 and is part of a group consisting of. Such a configuration can provide the advantages of efficient filling and delivery.

[0092] The pro-benefit agent preferably does not contain peptide bonds because it may be susceptible to attack by protease enzymes present, for example, in a treatment solution, under storage, treatment, or use conditions.

[0093] The pro-benefit agent preferably does not contain halogen because it may be limited by regulatory concerns.

[0094] Benefit agents and their fragments The pro-benefit agent compounds of the present disclosure include benefit agent fragments derived from aldehyde-containing benefit agents, ketone-containing benefit agents, or combinations thereof. The benefit agent fragment may be derived from a benefit agent containing an aldehyde moiety. The benefit agent fragment may be derived from a benefit agent containing a ketone moiety.

[0095] As used herein, the benefit agent from which the benefit agent fragment is derived may be referred to as the parent benefit agent.

[0096] The aldehyde or ketone moiety of the parent benefit agent may react with the nitrogen atom of the core of the compound (e.g., the nitrogen of an amino acid) and a second heteroatom, such that the carbon atom of the benefit agent fragment binds to the nitrogen atom and the second heteroatom to form part of a heterocyclic moiety (e.g., N-C-O when the second heteroatom is oxygen).

[0097] The complex ring moiety can be conveniently formed from such agents, for example, without the need for a catalyst or substantial thermal energy input, so the parent beneficial agent may preferably contain an aldehyde moiety.

[0098] When the bond of the fragment to the complex ring moiety is broken, for example, by hydrolysis, the beneficial agent is released. The relevant bond can be broken through trigger conditions such as the presence of water or an increase in temperature.

[0099] The beneficial agent fragment can be derived from any suitable beneficial agent that can include a fragrance raw material, an antibacterial agent, a pesticide, an insect repellent, an antifungal agent, a herbicide, a hue dye, an antioxidant, a non-fragrance sensory stimulant (such as a cooling agent), or a combination thereof, preferably a fragrance raw material, an antibacterial agent, or a combination thereof, more preferably a fragrance raw material. Some of these beneficial agents are described in more detail below.

[0100] A. Fragrance raw materials The beneficial agent may be a fragrance raw material (「PRM」) that includes an aldehyde moiety, a ketone moiety, or a mixture thereof. The beneficial agent fragment (e.g., the Z group) can be derived from the fragrance raw material.

[0101] As used herein, the term 「fragrance raw material (or 「PRM」)」 refers to a compound having a molecular weight of at least about 100 g / mol (optionally up to about 1000 g / mol, preferably up to about 500 g / mol) that is useful in imparting an odor, aroma, essence, or fragrance, either alone or in combination with other fragrance raw materials. A list of common PRMs can be found in various references such as 「Perfume and Flavor Chemicals」 Volumes I and II; Steffen Arctander Allured Pub.Co. (1994) and 「Perfumes: Art, Science and Technology」, Miller, P.M. and Lamparsky, D., Blackie Academic and Professional (1994).

[0102] The flavoring raw material may preferably contain an aldehyde moiety in order to react favorably (e.g., in the absence of a catalyst) to form a heterocyclic moiety. Flavoring raw materials containing an aldehyde moiety are provided in Table B below. The materials provided in Table B are considered to be exemplary (but non-limiting) examples of PRMs suitable for use according to the present disclosure.

[0103]

Table 3-1

[0104]

Table 3-2

[0105] The flavoring raw material forming the beneficial agent fragment can be selected from the group consisting of the aldehyde-containing PRMs in Table A above. The PRM forming the PRM fragment may contain an aldehyde moiety, preferably methyl nonyl acetaldehyde, benzaldehyde, floralozone; isocyclocitral, triplal (ligustral), precyclocremone B, lilial; decyl aldehyde, undecyl aldehyde, cyclamen homonaldehyde, cyclamen aldehyde, dupical, oncidar, adoxal; melonal; calypsone; anisaldehyde, heliotropin; cuminaldehyde, scentenal; 3,6-dimethylcyclohex-3-ene-1-carbaldehyde, satenal, canthoxal; vanillin, ethyl vanillin, cinnamic aldehyde; cis-4-decenal, trans-4-decenal, cis-7-decenal, undecyl aldehyde, trans-2-hexenal; trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, floridol, butyl cinnamaldehyde, limonellal, amyl cinnamaldehyde, hexyl cinnamaldehyde, citronellal; citral; cis-3-hexen-1-al, and mixtures thereof.

[0106] As described above, the pro-beneficial agent compound may contain a fragment of a flavoring raw material containing a ketone moiety. The flavoring raw materials containing a ketone moiety are presented in Table C below. The materials presented in Table C are considered to be exemplary (but non-limiting) examples of PRMs suitable for use according to the present disclosure.

[0107] [Table 4-1]

[0108] [Table 4-2]

[0109] The flavor raw material forming the PRM fragment may be selected from the group consisting of the ketone-containing PRMs in Table C above. The PRM forming the PRM fragment may contain a ketone moiety, preferably selected from the group consisting of neroliol, 4-(4-methoxyphenyl)butan-2-one; 1-naphthalen-2-ylethanone, nectaryl, trimofix O, fluramone, δ-damascone, β-damascone, α-damascone, methyl ionone, 2-hexylcyclopenta-2-en-1-one; galavascone, and mixtures thereof.

[0110] The beneficial agent fragment can be derived from a beneficial agent that is a fragrance raw material, preferably selected from the group consisting of methyl nonyl acetaldehyde, benzaldehyde, floralozone; isocyclocitral, triplal (ligustral), precyclomone B, lilial; decyl aldehyde, undecylenic aldehyde, cyclamen homoaldehyde, cyclamen aldehyde, dupical, oncidar, adoxal; melonal; calypsone; anisaldehyde, heliotropin; cuminaldehyde, scentenal; 3,6-dimethylcyclohex-3-ene-1-carbaldehyde, satenal, canthoxal; vanillin, ethyl vanillin, cinnamic aldehyde; cis-4-decenal, trans-4-decenal, cis-7-decenal, undecylenic aldehyde, trans-2-hexenal; trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, floridol, cymeral, butyl cinnamic aldehyde, limonellal, amyl cinnamic aldehyde, hexyl cinnamic aldehyde, citronellal; citral; cis-3-hexen-1-yl, nerolione, 4-(4-methoxyphenyl)butan-2-one; 1-naphthalen-2-ylethanone, nectaryl, trimofix O, fluramon, δ-damascone, β-damascone, α-damascone, methyl ionone, 2-hexylcyclopenta-2-en-1-one; galavascone, and mixtures thereof.

[0111] When the beneficial agent fragment is derived from a beneficial agent that is a fragrance raw material, preferably the PRM listed in the previous paragraph, the first monovalent moiety and / or the second monovalent moiety may preferably be an organic group containing from about 8 to about 18 chain atoms, more preferably from about 10 to about 18 chain atoms, and preferably the chain atoms are carbon atoms. Such a chain length is considered to provide a suitable degree of hydrophobicity to promote the adhesion effect, particularly in laundry applications where the pro-beneficial agent compound is used in an aqueous liquid.

[0112] The flavoring raw materials in this specification, which include the flavoring raw materials listed above, can be obtained from one or more of International Flavors and Fragrances in New York, NY, USA; Givaudan in Vernier, Switzerland; Firmenich in Geneva, Switzerland; Symrise in Holzminden, Germany; Kao in Tokyo, Japan; Takasago in Tokyo, Japan; and Florasynth in Tel-Aviv, Israel.

[0113] B. Antibacterial agent The beneficial agent may be an antibacterial agent containing an aldehyde moiety, a ketone moiety, or a mixture thereof.

[0114] Examples of antibacterial agents suitable for use in the present beneficial agent compound include acetylacetone enolate, gossypol, nootkatone, or a mixture thereof.

[0115] When the beneficial agent fragment is derived from an antibacterial agent, preferably the antibacterial agents listed in the previous paragraph, the hydrophobic moiety may preferably be an organic group containing about 6 to about 12 chain atoms, and preferably the chain atoms are carbon atoms. Such a chain length is considered to provide a suitable degree of hydrophobicity to promote the antibacterial effect and to promote the desired interaction between the antibacterial agent and the target microorganism.

[0116] Pro-beneficial agent precursor compound The present disclosure relates to pro-beneficial agent precursor compounds useful for making the pro-beneficial agent compounds described herein.

[0117] A pro-beneficial agent precursor compound (or, when used herein, simply a "precursor compound") can include a carbon-containing core, which includes a carbon skeleton, one or more side groups, a nitrogen atom, and a carbonyl group, and the carbonyl group is part of a carbonyl-containing moiety selected from an ester moiety, an amide moiety, or a thioester moiety, and the carbonyl-containing moiety includes a first heteroatom bonded to the carbon of the carbonyl group, and the first heteroatom is selected from oxygen, nitrogen, or sulfur, and the carbonyl-containing moiety further includes a first monovalent moiety bonded to the first heteroatom, and the first monovalent moiety is an organic group containing 1 to 34 chain atoms, and the nitrogen atom is preferably an amine group containing a substitution, and the substitution includes a second heteroatom, and the second heteroatom is selected from oxygen, nitrogen, or sulfur. The substitution on the amine group may further include a second monovalent moiety as described above.

[0118] In fact, the precursor compound may be a pro-beneficial agent compound before reacting with the (first) beneficial agent. The core, side groups, carbonyl-containing moiety, first monovalent moiety, and second monovalent moiety are preferably as described above.

[0119] The pro-beneficial agent precursor compound may be characterized by a structure according to Formula VI, HG’-(J) d -A-Q Formula VI, wherein the J group is bonded to the nitrogen atom of the A group, and A, J, subscript d, G’, and Q are substantially as described above.

[0120] The precursor compound may be characterized by a structure according to Formula VII,

[0121]

Chemical formula

[0122] The precursor compound can be prepared by modifying a suitable parent core compound such as a parent amino acid. For example, the carboxyl group of an amino acid having a compound represented by the following formula H-G-Q is, for example, through an esterification, amidation, or thioesterification reaction. Suitable H-G-Q feedstocks may preferably be alcohols, fatty alcohols, and / or diols. The obtained compound may be further modified to carry out a heteroatom-containing substitution with an amine group. For example, the amine group may be reacted with oxirane to obtain an alkanolamine group. Then, the alkanolamine group may be reacted with a suitable beneficial agent to form a heterocyclic moiety.

[0123] Exemplary precursor compounds and methods for making such compounds are provided in the section of the following synthesis examples.

[0124] Method for making pro-beneficial agent compounds The present disclosure also relates to a method for making pro-beneficial agent compounds. Such a method includes the step of reacting a pro-beneficial agent precursor compound with a suitable beneficial agent. Such precursor compounds and beneficial agents are described above. Such a reaction can occur in a premix composition, in a treatment composition, or even on a surface or article such as a fabric or clothing.

[0125] Exemplary methods for making such compounds are provided in the section of the following synthesis examples.

[0126] Premix composition The present disclosure further relates to certain premix compositions and methods for making such compositions. The premix can be conveniently prepared prior to the product formulation, prepared at one manufacturing site, and transported to another manufacturing site for the product formulation.

[0127] The premix composition may include a pro-beneficial agent precursor compound (this precursor compound is as described above) and a beneficial agent (this beneficial agent is as described above). The selections described above regarding the pro-beneficial agent compound, its components, and / or its precursors apply equally here.

[0128] For example, the premix composition may contain a pro-beneficial agent precursor compound, and the precursor compound is characterized by the structure according to Formula VII,

[0129]

Chemical formula

[0130] For reasons of packing efficiency, it is preferable to reasonably match the molar amount of the beneficial agent, preferably the first beneficial agent, with the molar amount of the above-mentioned carrier molecule (here, the pro-beneficial agent precursor compound). For example, the premix composition may contain the pro-beneficial agent precursor compound and the beneficial agent in a molar ratio of about 3:1 to about 1:3, preferably about 2:1 to about 1:2, preferably about 1.5:1 to about 1:1.5, more preferably about 1.2:1 to about 1:1.2, and even more preferably about 1:1.

[0131] Even more specifically, for reasons of packing efficiency, it is preferable to reasonably match the molar amount of the beneficial agent with the molar equivalent of the reactive functional group (for example, preferably an amine group) of the carrier molecule (here, the pro-beneficial agent precursor compound). For example, the premix composition may contain the pro-beneficial agent precursor compound and the reactive functional group (for example, preferably an amine group) of the beneficial agent in a molar ratio of about 3:1 to about 1:3, preferably about 2:1 to about 1:2, preferably about 1.5:1 to about 1:1.5, more preferably about 1.2:1 to about 1:1.2, and even more preferably about 1:1.

[0132] When the pro-beneficial agent precursor compound contains a plurality of binding sites or a plurality of functional groups capable of forming such binding sites for the beneficial agent and optionally a second beneficial agent, the premix composition is present in a molar ratio of about 3:1 to about 1:3, preferably about 2:1 to about 1:2, preferably about 1.5:1 to about 1:1.5, more preferably about 1.2:1 to about 1:1.2, and even more preferably about 1:1 of the pro-beneficial agent precursor compound and the beneficial agent (and optionally a second beneficial agent that can also bind to the precursor compound). Such ratios may be useful for maximizing filling and / or delivery efficiency.

[0133] The premix composition may be in the form of a pure fluid and may contain little or no water. In such cases, it may be desirable to include a water scavenger such as magnesium sulfate in the premix and / or physically remove water via a molecular sieve or in a vacuum. The premix composition may contain less than about 10 wt%, preferably less than about 5 wt%, more preferably less than about 1 wt%, and even more preferably less than about 0.1 wt% water of the premix composition. A low-moisture premix composition may be particularly preferred when it is intended to be formulated into a low-moisture product composition such as a solid like a pastille or a dense formulation such as a unit-dose composition encapsulated in a water-soluble film. When the premix is a low-moisture premix, the premix may contain from about 1 wt% to about 100 wt%, preferably from about 5 wt% to about 100 wt%, more preferably from about 20 wt% to about 100 wt% of the pro-beneficial agent compound of the premix composition. When the premix is a low-moisture premix, the premix may contain from about 0.01 wt% to about 80 wt%, preferably from about 0.01 wt% to about 20 wt% of the pro-beneficial agent precursor compound of the premix composition. When the premix is a low-moisture premix, the premix may contain from about 0.01 wt% to about 80 wt%, preferably from about 0.01 wt% to about 20 wt% of the beneficial agent of the premix composition.

[0134] The premix composition may contain water. The premix composition may be in the form of an emulsion, preferably an oil-in-water emulsion. If the premix is in the form of an emulsion and contains water, the water may be present at a concentration of about 50% to about 95% by weight, preferably about 60% to about 90% by weight of the premix composition. If the premix contains water, the pro-beneficial agent precursor compound may be added at a concentration of about 0.01% to about 7.5% by weight of the premix composition. If the premix contains water, the beneficial agent may be added at a concentration of about 0.01% to about 7.5% by weight of the premix composition.

[0135] In the premix composition, the precursor compound and the beneficial agent may react as described above to form the pro-beneficial agent compound. The precursor compound, the beneficial agent, and the pro-beneficial agent compound may all be present in equilibrium. The formation of the pro-beneficial agent compound according to the present disclosure typically produces water via a condensation process that forms a heterocycle, so the equilibrium may shift towards the reactant side of the reaction (e.g., the precursor compound and the beneficial agent) if the premix contains water. Conversely, if the premix is substantially free of intentionally added water, a relatively large amount of the pro-beneficial agent compound may be present, but it is recognized that water is formed as a result of the condensation reaction.

[0136] The total weight percentage of the pro-beneficial agent precursor, the beneficial agent, and, if present, the pro-beneficial agent compound may be about 10% to about 100% by weight, preferably about 25% to about 100% by weight, more preferably about 50% to about 100% by weight, and even more preferably about 75% to about 100% by weight of the premix composition.

[0137] The premix composition or a portion thereof can be obtained by mixing about 1 part by weight to about 99 parts by weight, preferably about 5 parts by weight to about 80 parts by weight of the pro-beneficial agent precursor compound with about 1 part by weight to about 99 parts by weight, preferably about 5 parts by weight to about 80 parts by weight of the beneficial agent, and the resulting mixture is understood to constitute 100 parts by weight in total.

[0138] The premix composition may include a plurality of precursors, a plurality of beneficial agents, and / or a plurality of pro-beneficial agent compounds. The premix composition may further include additional agents that do not react to form the pro-beneficial agent compounds according to the present disclosure. For example, the premix composition may include additional PRM, surfactants, solvents, or other processing aids or stabilizing aids.

[0139] The premix composition may include a surfactant, preferably a nonionic surfactant. The surfactant may be useful for the stability of the premix composition and / or the emulsification process.

[0140] The present disclosure further relates to a method for preparing such an aromatic premix composition. The method may include mixing a pro-beneficial agent precursor (e.g., according to Formula IV or V described herein) with a beneficial agent described herein, and the beneficial agent includes an aldehyde moiety, a ketone moiety, or a combination thereof. The materials may be mixed in the proportions provided above. The method may include removing free water or otherwise binding it, which may help drive the reaction in the premix towards the product (e.g., the pro-beneficial agent compound). If the premix composition contains water, the precursor compound and water may preferably be mixed before the beneficial agent is added. Alternatively, the beneficial agent and water may be mixed before the beneficial agent is added.

[0141] Treatment composition The present composition relates to a treatment composition comprising an auxiliary component and a pro-beneficial agent compound as described above.

[0142] The treatment composition may be a consumer product composition. The consumer product compositions of the present disclosure may be useful in baby care, beauty care, fabric care, home care, family care, feminine care, and / or health care applications. The treatment composition may be useful for treating surfaces such as fabrics, hair, or skin. The consumer product composition may be intended to be used or consumed in the manner in which it is sold. The consumer product composition may not be intended for subsequent commercial manufacture or modification.

[0143] The treatment composition can be a household care composition. The treatment composition may be a fabric care composition, a hard surface cleaner composition, a dish care composition, a hair care composition (such as shampoo or conditioner), a body cleansing composition, or a mixture thereof.

[0144] The treatment composition may be a fabric care composition such as a laundry detergent composition (including a heavy-duty liquid detergent or unit-dose articles), a fabric conditioning composition (including a liquid fabric softening composition and / or a fabric strengthening composition), a laundry additive, a fabric pretreatment composition (including a spray, a pourable liquid, or a spray), a fabric refresher composition (including a spray), or a mixture thereof.

[0145] The treatment composition may be a beauty care composition, for example, a hair treatment product (including shampoo and / or conditioner), a skin care product (including creams, lotions, or other topical application products for consumer use), a shaving care product (including shaving lotion, foam, or a pre-shave or post-shave treatment), a personal cleansing product (including a liquid body wash, a liquid hand soap, and / or a bar soap), a deodorant and / or an antiperspirant, or a mixture thereof.

[0146] The treatment composition can be a home care composition such as air care, car care, dishwashing, hard surface cleaning and / or treatment, and other cleaning for consumers or businesses.

[0147] The treatment composition may be in the form of a liquid composition, a granular composition, a hydrocolloid, a single-compartment pouch, a multi-compartment pouch, a soluble sheet, a pastille or beads, a fibrous article, a tablet, a stick, a bar, flakes, a foam or a mousse, a non-woven sheet, or a mixture thereof.

[0148] The treatment composition may be in liquid form. The liquid composition may contain from about 30 wt% or from about 40 wt% or from about 50 wt% to about 99 wt% or to about 95 wt% or to about 90 wt% or to about 75 wt% or to about 70 wt% or to about 60 wt% of water of the composition. The liquid composition can be a liquid laundry detergent, a liquid fabric softener, a liquid dishwashing detergent, a hair shampoo, a hair conditioner, or a mixture thereof.

[0149] The treatment composition may be in solid form. The solid composition may be a powdery or granular composition. Such a composition may be agglomerated or spray-dried. Such a composition may include a plurality of granules or particles, at least some of which may include a plurality of granules or particles containing different compositions. The composition may be a powdery or granular cleaning composition that may contain a bleaching agent. The composition may be in the form of beads or pastilles, which may be formed into tablets from a liquid melt. The composition may be an extruded product.

[0150] The treatment composition may be in particulate form such as a plurality of fine particles. Each individual fine particle may have a mass of about 1 mg to about 1 g. The emulsion may be dispersed in a water-soluble carrier. The water-soluble carrier may be selected from the group consisting of polyethylene glycol, sodium acetate, sodium bicarbonate, sodium chloride, sodium silicate, polypropylene glycol polyoxoalkylene, polyethylene glycol fatty acid ester, polyethylene glycol ether, sodium sulfate, starch, and mixtures thereof. The water-soluble carrier may be a water-soluble polymer. When the treatment composition is in particulate form, it may contain from about 25 wt% to about 99.99 wt% of a water-soluble carrier and from about 0.001 wt% to about 50 wt% of a water-soluble carrier of the pro-beneficial agent compound. The particulate form may be in the form of beads or pastilles.

[0151] The treatment composition may be in the form of a single-use article such as a tablet, pouch, sheet, or fibrous article. Such a pouch typically includes a water-soluble film that at least partially encapsulates the composition, such as a polyvinyl alcohol water-soluble film. Suitable films are available from MonoSol, LLC (Indiana, USA). The composition can be encapsulated in a single-compartment pouch or a multi-compartment pouch. The multi-compartment pouch may have at least two, at least three, or at least four compartments. The multi-compartment pouch may include compartments arranged side by side and / or stacked. The composition contained in the pouch or its compartments may be a liquid, solid (such as powder), or a combination thereof. The composition in the form of a pouch may have a relatively small amount of water, for example, less than about 20% by weight, or less than about 15% by weight, or less than about 12% by weight, or less than about 10% by weight, or less than about 8% by weight of water in the detergent composition.

[0152] The treatment composition may be in the form of a spray and may be dispensed, for example, from a bottle via a trigger sprayer and / or from an aerosol container having a valve.

[0153] The treatment composition is -1 and at 21 °C, may have a viscosity of 1 to 1500 centipoise (1 to 1500 mPa·s), 100 to 1000 centipoise (100 to 1000 mPa·s), or 200 to 500 centipoise (200 to 500 mPa·s).

[0154] The treatment composition may contain a pro-beneficial agent compound in an amount of about 0.001% to about 30% by weight of the treatment composition, preferably about 0.001% to about 20% by weight, more preferably about 0.001% to about 15% by weight, 0.001% to about 10% by weight, preferably about 0.01% to about 5% by weight.

[0155] The treatment composition may contain a pro-beneficial agent compound in an amount sufficient to deliver a beneficial agent released by the pro-beneficial agent compound in an amount of about 0.01% to about 10% by weight of the treatment composition, preferably about 0.1% to about 5% by weight.

[0156] Auxiliary components The disclosed treatment compositions that can be consumer products may include auxiliary materials. The auxiliary materials may provide benefits in the intended end use of the composition or may be processing aids and / or stabilizing aids.

[0157] Suitable auxiliary materials can include surfactants, conditioning agents, adhesion aids, rheology modifiers or structuring agents, antioxidants, bleaching systems, stabilizers, builders, chelating agents, migration inhibitors, dispersants, enzymes and enzyme stabilizers, catalytic metal complexes, polymeric dispersants, clays and soil release / redeposition inhibitors, optical brighteners, foam suppressants, silicones, hue agents, aesthetic dyes, additional fragrances and fragrance delivery systems, structure elasticizers, carriers, hydrotropes, processing aids, structuring agents, antiagglomerants, coating agents, formaldehyde scavengers, and / or pigments.

[0158] Depending on the intended form, formulation, and / or end use, the compositions of the present disclosure may or may not contain one or more of the following auxiliary materials: surfactants, conditioning agents, adhesion aids, rheology modifiers or structuring agents, antioxidants, bleach activators, surfactants, builders, chelating agents, migration inhibitors, dispersants, enzymes and enzyme stabilizers, catalytic metal complexes, polymeric dispersants, clays and soil release / redeposition inhibitors, optical brighteners, foam suppressants, dyes, additional fragrances, fragrance delivery systems, structure elasticizers, fabric softeners, carriers, hydrotropes, processing aids, structuring agents, antiagglomerants, coating agents, formaldehyde scavengers, and / or pigments.

[0159] The exact nature of these additional components and the concentrations at which they are incorporated depend on the physical form of the composition and the nature of the operations being performed. However, when one or more auxiliary agents are present, such one or more auxiliary agents can be present as detailed below. The following is a non-limiting list of suitable additional auxiliary agents.

[0160] A. Surfactants The treatment compositions of the present disclosure may include surfactants. The surfactants may be useful, for example, for providing cleaning benefits. The composition may include a surfactant system that may contain one or more surfactants.

[0161] The treatment compositions of the present disclosure may include a surfactant system in an amount of about 0.1 wt% to about 70 wt%, or about 2 wt% to about 60 wt%, or about 5 wt% to about 50 wt% of the composition. The liquid composition may include a surfactant system in an amount of about 5 wt% to about 40 wt% of the composition. Compositions suitable for dense formulations, such as dense, liquid, gel, and / or unit dose forms, may include a surfactant system in an amount of about 25 wt% to about 70 wt%, or about 30 wt% to about 50 wt% of the composition.

[0162] The surfactant system may include anionic surfactants, nonionic surfactants, zwitterionic surfactants, cationic surfactants, amphoteric surfactants, or combinations thereof. The surfactant system may include linear alkylbenzene sulfonates, alkyl ethoxylated sulfates, alkyl sulfates, nonionic surfactants such as ethoxylated alcohols, amine oxides, or mixtures thereof. The surfactants may be at least partially derived from natural resources such as natural feedstock alcohols.

[0163] Suitable anionic surfactants may include any conventional anionic surfactant. This may include, for example, sulfate detergency surfactants for alkoxylated and / or non-alkoxylated alkyl sulfate materials, and / or sulfonic acid-based detergency surfactants such as alkylbenzene sulfonate. The anionic surfactant may be linear, branched, or a combination thereof. Preferred surfactants include linear alkyl benzene sulfonate (LAS), alkyl ethoxylated sulfate (AES), alkyl sulfate (AS), or mixtures thereof. Other suitable anionic surfactants include branched modified alkyl benzene sulfonate (MLAS), methyl ester sulfonate (MES), sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), and / or alkyl ethoxylated carboxylate (AEC). The anionic surfactant may be present in acid form, salt form, or a mixture thereof. The anionic surfactant may be partially or wholly neutralized, for example, by an alkali metal (e.g., sodium) or an amine (e.g., monoethanolamine).

[0164] The surfactant system may contain a nonionic surfactant. Suitable nonionic surfactants include alkoxylated fatty alcohols such as ethoxylated fatty alcohols. Other suitable nonionic surfactants include alkoxylated alkylphenols, alkylphenol condensates, medium-chain branched alcohols, medium-chain branched alkyl alkoxylates, alkyl polysaccharides (e.g., alkyl polyglycosides), polyhydroxy fatty acid amides, ether-capped poly(oxyalkylated) alcohol surfactants, and mixtures thereof. The alkoxylate units may be ethyleneoxy units, propyleneoxy units, or mixtures thereof. The nonionic surfactant may be linear, branched (e.g., medium-chain branched), or a combination thereof. Certain nonionic surfactants may include alcohols having an average of about 12 to about 16 carbons and an average of about 3 to about 9 ethoxy groups, such as a C12-C14 EO7 nonionic surfactant.

[0165] Suitable zwitterionic surfactants include betaines such as alkyldimethylbetaine and cocoamidopropyl betaine, C8-C 18 (e.g., C 12 -C 18 ) amine oxides (e.g., C 12 - 14 dimethylamine oxide), and / or N-alkyl-N,N-dimethylamino-1-propanesulfonate (where the alkyl group may be C8-C 18 or C 10 -C 14 ) and other conventional zwitterionic surfactants such as sulfobetaines and hydroxybetaines. The zwitterionic surfactant may include amine oxide.

[0166] Depending on the complex and / or the intended end use, the composition may substantially not contain a particular surfactant. For example, a liquid fabric enhancing composition such as a fabric softener may substantially not contain an anionic surfactant because such surfactants can negatively interact with the cationic component.

[0167] B. Conditioning Active Substances The treatment compositions of the present disclosure may contain a conditioning active substance. Compositions containing a conditioning active substance may provide benefits related to softness, wrinkle prevention, antistatic properties, conditioning, anti-extension, color, and / or appearance.

[0168] The conditioning active substance may be present at a level of about 1 wt% to about 99 wt% of the composition. The composition may contain from about 1 wt% of the composition, or from about 2 wt%, or from about 3 wt%, up to about 99 wt%, or up to about 75 wt%, or up to about 50 wt%, or up to about 40 wt%, or up to about 35 wt%, or up to about 30 wt%, or up to about 25 wt%, or up to about 20 wt%, or up to about 15 wt%, or up to about 10 wt% of the conditioning active substance. The composition may contain from about 5 wt% to about 30 wt% of the conditioning active substance of the composition.

[0169] Suitable conditioning active substances for the compositions of the present disclosure include quaternary ammonium ester compounds, silicones, non-ester quaternary ammonium compounds, amines, fatty acid esters, sucrose esters, silicones, dispersible polyolefins, polysaccharides, fatty acids, softening or conditioning oils, polymer latexes, polyhydroxystearic acid and / or its derivatives, glyceride copolymers, or combinations thereof. Preferably, the conditioning active substance is a cationic conditioning active substance, which can improve the delivery / attachment of pro-beneficial agent compounds.

[0170] The treatment composition may contain a conditioning active substance, and the conditioning active substance contains a quaternary ammonium ester compound. Preferably, the quaternary ammonium ester compound is present in the treatment composition at a concentration of about 2% to about 35% by weight, preferably about 4% to about 25% by weight, more preferably about 5% to about 20% by weight, even more preferably about 6% to about 15% by weight, and even more preferably about 7% to about 12% by weight. The quaternary ammonium ester compound (also known as "esterquat") may be a monoesterquat, a diesterquat, a triesterquat, or a combination thereof. Preferably, the diesterquat material forms the major part (whether in majority or plural) of the esterquat compound. In addition to providing a conditioning effect, it is believed that by selecting an appropriate type and / or concentration of the conditioning active substance (i.e., the quaternary ammonium ester compound), the adhesion and / or performance of the pro-beneficial agent compound described in the present disclosure can be improved.

[0171] The quaternary ammonium ester compound may contain a compound according to the following formula, {R 2 (4-m) -N+-[X-Y-R 1 m}A - In the formula, m is 1, 2, or 3, provided that each value of m is the same, Each R which may contain 13 to 22 carbon atoms 1 is independently a linear hydrocarbyl group or a branched hydrocarbyl group, preferably, R 1 is linear, more preferably, R 1 is a partially unsaturated linear alkyl chain, Each R 2 is independently a C1-C3 alkyl group or a hydroxyalkyl group, and / or each R 2 ​is selected from methyl, ethyl, propyl, hydroxyethyl, 2-hydroxypropyl, 1-methyl-2-hydroxyethyl, poly(C2-C3 alkoxy), polyethoxy, benzyl, more preferably methyl or hydroxyethyl, each X is independently -(CH2)n-, -CH2-CH(CH3)- or -CH(CH3)-CH2-, each n is independently 1, 2, 3 or 4, preferably each n is 2, each Y is independently -O-(O)C- or -C(O)-O-, and A- is independently selected from the group consisting of chloride, bromide, methyl sulfate, ethyl sulfate, sulfuric acid, and nitric acid, preferably A- is selected from the group consisting of chloride and methyl sulfate, more preferably A- is methyl sulfate, a quaternary ammonium ester compound.

[0172] In the case of monoester quats, m is 1. In the case of diester quats, m is 2. For triester quats, m is 3. The conditioning active may include a mixture of monoester quats and diester quats, or even a mixture of monoester quats, diester quats, and triester quats. As will be understood by those skilled in the art, the mixture may depend in part on starting / supply feedstock materials such as dialkanolamine or trialkanolamine.

[0173] The quaternary ammonium ester compound can be derived from a fatty acid characterized by an iodine value of 0 to 140, or 0 to about 90, or about 10 to about 70, or about 15 to about 50, or about 18 to about 30. The iodine value can be determined by the method presented in US Patent Application Publication No. 2020 / 0407665 (corresponding to International Publication No. 2020 / 264566).

[0174] This composition may contain a quaternary ammonium ester compound, a silicone, or a combination of multiple sets of these, preferably a combination of one set. The total amount of the quaternary ammonium ester compound and the silicone may be about 5 wt% to about 70 wt%, or about 6 wt% to about 50 wt%, or about 7 wt% to about 40 wt%, or about 10 wt% to about 30 wt%, or about 15 wt% to about 25 wt% of the composition. The composition may contain the quaternary ammonium ester compound and the silicone in a weight ratio of about 1:10 to about 10:1, or about 1:5 to about 5:1, or about 1:3 to about 1:3, or about 1:2 to about 2:1, or about 1:1.5 to about 1.5:1, or about 1:1.

[0175] The composition may contain a mixture of different types of conditioning active substances. The compositions of the present disclosure may contain a specific conditioning active substance, but may not substantially contain other conditioning active substances. For example, the composition may not contain a quaternary ammonium ester compound, a silicone, or both. The composition may contain a quaternary ammonium ester compound, but may not substantially contain a silicone. The composition may contain a silicone, but may not substantially contain a quaternary ammonium ester compound.

[0176] The conditioning active substance may include a glyceride copolymer. The glyceride copolymer may be derived from natural oils. Examples of natural oils include, but are not limited to, vegetable oils, algal oils, fish oils, animal fats, tall oil, derivatives of these oils, combinations of any of these oils, etc. Representative non-limiting examples of vegetable oils include low erucic acid rapeseed oil (canola oil), high erucic acid rapeseed oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, linseed oil, palm kernel oil, camellia oil, jatropha oil, mustard oil, pennycress oil, camelina oil, hempseed oil, and castor oil, preferably canola oil. Representative non-limiting examples of animal fats include lard, tallow, poultry oil, yellow grease, and fish oil. Tall oil is a by-product of wood pulp production. The glyceride copolymer may be a metallized unsaturated polyol ester.

[0177] C. Adhesion Aid The treatment composition of the present disclosure may include an adhesion aid. The adhesion aid can promote the adhesion of various beneficial agents including the pro-beneficial agent compounds, conditioning active substances, fragrances or fragrance delivery systems (such as encapsulated fragrances), or combinations thereof of the present disclosure, improve the performance effects of the composition, and / or enable more efficient formulation of such beneficial agents. The composition may include from 0.0001 wt% to 3 wt%, preferably from 0.0005 wt% to 2 wt%, more preferably from 0.001 wt% to 1 wt%, or about 0.01 wt% to about 0.5 wt%, or about 0.05 wt% to about 0.3 wt% of the adhesion aid. The adhesion aid may be a cationic or amphoteric polymer, preferably a cationic polymer.

[0178] General cationic polymers and methods for their production are well known in the literature. Suitable cationic polymers include quaternary ammonium polymers known as "polyquaternium" polymers named by the International Nomenclature of Cosmetic Ingredients, for example, polyquaternium-6 (poly(diallyldimethylammonium chloride)), polyquaternium-7 (copolymer of acrylamide and diallyldimethylammonium chloride), polyquaternium-10 (quaternized hydroxyethyl cellulose), polyquaternium-22 (copolymer of acrylic acid and diallyldimethylammonium chloride).

[0179] The adhesion aid may be selected from the group consisting of polyvinylformamide, partially hydroxylated polyvinylformamide, polyvinylamine, polyethyleneimine, ethoxylated polyethyleneimine, polyvinyl alcohol, polyacrylate, and combinations thereof.

[0180] The cationic polymer may contain cationic acrylate and / or methacrylate. Such a polymer may be a copolymer further containing a nonionic monomer such as acrylamide, for example. The cationic polymer may be linear or crosslinked. The adhesion aid may include a combination of a linear cationic polymer and a crosslinked cationic polymer.

[0181] The adhesion aid can be added to the fabric treatment composition simultaneously with the delivery particles (e.g., simultaneously with an encapsulated beneficial agent such as an encapsulated fragrance) or directly / independently. The weight average molecular weight of the polymer, when measured by size exclusion chromatography against a polyethylene oxide standard using refractive index (RI) detection, may be from 500 Daltons to 5,000,000 Daltons, or from 1000 Daltons to 2,000,000 Daltons, or from 2500 Daltons to 1,500,000 Daltons. The weight average molecular weight of the cationic polymer may be from 5000 Daltons to 37,500 Daltons.

[0182] D. Fragrance and / or fragrance delivery system The treatment compositions of the present disclosure may include a fragrance and / or a fragrance delivery system. This may apply even when the beneficial agent fragment of the pro-beneficial agent compound is derived from a fragrance raw material.

[0183] The treatment compositions of the present disclosure may include other fragrance raw materials, for example, in pure or free form, including PRMs that do not contain aldehyde or ketone moieties. For example, other PRMs may be provided as pure oil or free oil in the premix composition and / or treatment composition according to the present disclosure, even if they do not react with the pro-beneficial agent precursor compound. Such mixtures may be desirable, for example, to provide a more appropriate olfactory experience.

[0184] The treatment compositions of the present disclosure may further include a pure fragrance, preferably a pure fragrance raw material that does not contain an aldehyde or ketone moiety. Preferably, the pure fragrance includes an alcohol-containing fragrance raw material. Suitable alcohol-containing fragrance raw materials are known to those skilled in the art and may include geraniol, citronellol, cinnamic alcohol, eugenol, etc. That being said, the pure fragrance may further include a free fragrance raw material that contains an aldehyde and / or a ketone moiety.

[0185] The treatment compositions of the present disclosure may additionally or alternatively include a fragrance delivery system. Such a fragrance delivery system may take the form of a polymer-assisted delivery system. Such a fragrance delivery system may take the form of an encapsulation, for example, a core-shell encapsulation, where the core contains the fragrance raw material and is surrounded by a polymer shell. The polymer shell may include a polymer material derived from polyacrylate, polyurea, polyurethane, polysaccharide, polyvinyl alcohol, melamine, derivatives thereof, or combinations thereof. Additionally or alternatively, a suitable fragrance delivery system may include known pro-fragrance / pro-aromatic materials.

[0186] Other materials The treatment composition, and / or further the premix composition, of the present disclosure may contain unreacted reactants and / or degradation products of the pro-beneficial agent compounds described herein. For example, the treatment composition and / or premix composition of the present disclosure may be a precursor or derivative of a carbon-containing core alone such as a parent amino acid (e.g., H2-A-H, where A is as substantially defined above by Formula III and G = oxygen), a modified amino acid having a first monovalent moiety (e.g., H2-A-Q, where A is substantially as defined above by Formula III), a free form of the first monovalent moiety (e.g., H-G-Q such as a fatty alcohol like dodecanol), a form of the pro-beneficial agent compound that does not contain the first monovalent moiety (e.g., contains a heterocyclic moiety but does not contain the first monovalent moiety), a free beneficial agent, e.g., an aldehyde or ketone-containing PRM, or a combination thereof. Other materials that may be present can include a solvent or diluent, a free oxirane precursor, a residual catalyst salt, or a combination thereof.

[0187] Method for manufacturing the treatment composition The present disclosure relates to a manufacturing process for any of the compositions described herein. The process for making a treatment composition that can be a consumer product may include the step of mixing a pro-beneficial agent compound described herein with an auxiliary material described herein.

[0188] The pro-beneficial agent compound can be mixed with such auxiliary materials by a method including mixing and / or spraying.

[0189] The compositions of the present disclosure can be formulated in any suitable form and can be prepared by any process selected by the formulator. The pro-beneficial agent compound and the auxiliary materials may be combined in a batch process, a circulation loop process, and / or an in-line mixing process. Suitable apparatuses for use in the processes disclosed herein include continuous stirred tank reactors, homogenizers, turbine agitators, recirculation pumps, paddle mixers, high-shear mixers, static mixers, plow shear mixers, ribbon blenders, vertical axis granulators, and drum mixers (all of which are batch-type and, where available, of continuous process configuration), spray dryers, and extrusion molding machines.

[0190] For example, the method for preparing the treatment composition may include the step of mixing the pro-beneficial agent compound according to the present disclosure with a base composition, preferably a liquid base composition, and the base composition includes auxiliary components. This process can be carried out, for example, in a batch process or an in-line mixing process, preferably an in-line mixing process.

[0191] The method for preparing the treatment composition may include the step of mixing a pro-beneficial agent precursor compound, a beneficial agent, and auxiliary components as described herein. Preferably, the auxiliary components are part of the base composition, and the pro-beneficial agent precursor compound and the beneficial agent are added to the base composition as separate inputs. The separate inputs may be added sequentially (e.g., continuously) or substantially simultaneously. Preferably, the base composition is liquid. This process can be carried out, for example, in a batch process or an in-line mixing process, preferably an in-line mixing process.

[0192] The method for preparing the treatment composition may include the step of adding a premix to the base composition. The premix composition may contain a pro-beneficial agent precursor compound and a beneficial agent as described herein. The premix composition can be obtained by combining a pro-beneficial agent precursor compound and a beneficial agent as described herein. The premix composition may contain a pro-beneficial agent compound according to the present disclosure, for example, resulting from the reaction of the precursor compound and the beneficial agent. The premix composition may contain a mixture of a pro-beneficial agent precursor compound, a beneficial agent, and a pro-beneficial agent compound. The premix may optionally contain water. This process can be carried out, for example, in a batch process or an in-line mixing process, preferably an in-line mixing process. The premix may be in solid form, such as a PEG-based pastille, or may be particularly preferred when preparing a treatment composition in solid form. In such cases, the removal or reduction of water from the premix can be useful, for example, via a water scavenger such as magnesium sulfate, or via the use of molecular sieves or distillation in vacuo.

[0193] Method for treating a surface The present disclosure further relates to a method for treating a surface (e.g., the surface of an article) with a treatment composition according to the present disclosure. Such a method can provide benefits related to cleaning, conditioning, hygiene, and / or deodorization.

[0194] Suitable surfaces can include fabrics (including clothing, towels, or linens), hard surfaces (such as tiles, porcelain, linoleum, or wooden floors), tableware, hair, skin, or mixtures thereof.

[0195] The method may include contacting the article or surface, optionally in the presence of water, with the treatment composition of the present disclosure, and may further optionally include the steps of rinsing and / or drying the article or surface. The treatment composition may be in undiluted form or may be diluted with a liquid, such as a cleaning or rinsing liquid. The treatment composition may be diluted with water before, during, or after contact with the surface or article. The surface or article comprising the surface may optionally be washed and / or rinsed before and / or after the contacting step.

[0196] The method for treating and / or cleaning a surface may comprise the following steps. a) Optionally, the steps of washing, rinsing, and / or drying the surface; b) Optionally, contacting the surface with the treatment composition described herein, in the presence of water; c) Optionally, the steps of washing and / or rinsing the surface, and d) Optionally, drying the surface by passive drying and / or by an active method such as a washing dryer.

[0197] For the purposes of the present invention, washing includes, but is not limited to, scrubbing and mechanical agitation. The fabric may include any fabric that can be laundered or treated under normal consumer, commercial, or industrial use conditions.

[0198] The liquid that may contain the disclosed composition may have a pH of from about 3 to about 11.5. When diluted, such compositions are typically used at a concentration of from about 500 ppm to about 15,000 ppm in solution. When the cleaning solvent is water, the water temperature is typically in the range of from about 5°C to about 90°C, and when the surface is part of a fabric, the weight ratio of water to fabric is typically from about 1:1 to about 30:1.

[0199] The present disclosure further discloses a method for treating a surface or an article, preferably a fabric, with an aqueous treatment liquid containing a pro-beneficial agent compound according to the present disclosure, preferably a method in which the beneficial agent fragment is a fragment of a fragrance raw material or an antibacterial agent, preferably a fragment of a fragrance raw material. The process may include contacting the article, preferably the fabric, with the aqueous liquid. The pro-beneficial agent compound may be present in the aqueous liquid at a concentration of about 0.001 weight ppm (e.g., 1 ppb) to about 1000 weight ppm.

[0200] The present disclosure further discloses a method for treating a surface or an article, preferably a fabric, with an aqueous treatment liquid containing a pro-beneficial agent precursor compound according to the present disclosure and a beneficial agent according to the present disclosure. The beneficial agent may be a fragrance raw material or an antibacterial agent, preferably a fragrance raw material. The process may include contacting the article, preferably the fabric, with the aqueous liquid. The pro-beneficial agent precursor compound may be present in the aqueous liquid at a concentration of about 0.01 ppm (e.g., 1 ppb) to about 1000 ppm by weight.

[0201] Use The present disclosure relates to the use of the pro-beneficial agent compound described herein for providing a freshness effect when the pro-beneficial agent compound contains a fragment of a fragrance raw material, particularly when it is part of a treatment composition.

[0202] The present disclosure relates to the use of the pro-beneficial agent compound described herein for providing an antibacterial effect when the pro-beneficial agent compound contains a fragment of an antibacterial agent, particularly when it is part of a treatment composition.

[0203] The present disclosure relates to the use of the pro-beneficial agent compound described herein for providing a malodor prevention effect, particularly when it is part of a treatment composition.

[0204] Combination The specifically contemplated combinations of the present disclosure are described in the following alphabetized paragraphs herein. These combinations are for illustrative purposes essentially and are not intended to be limiting.

[0205] A. Regarding a pro-beneficial agent compound, the compound has a carbon-containing core, the carbon-containing core includes a carbon skeleton, one or more side groups, a nitrogen atom, and a carbonyl group, the carbonyl group is part of a carbonyl-containing moiety selected from an ester moiety, an amide moiety, or a thioester moiety, the carbonyl-containing moiety includes a first heteroatom bonded to the carbon of the carbonyl group, the first heteroatom is selected from oxygen, nitrogen, or sulfur, the carbonyl-containing moiety further includes a first monovalent moiety bonded to the first heteroatom, the first monovalent moiety is an organic group containing 1 to 34 chain atoms, a carbon-containing core, and a beneficial agent fragment, where the carbon atoms of the beneficial agent fragment, the nitrogen of the carbon-containing core, and a second heteroatom are part of a heterocyclic moiety, the second heteroatom is selected from oxygen, nitrogen, or sulfur, the second heteroatom is not part of a side group of the core, the carbon atoms of the beneficial agent fragment are bonded to the nitrogen and the second heteroatom, the beneficial agent fragment is derived from a beneficial agent, the beneficial agent includes an aldehyde moiety, a ketone moiety, or a combination thereof, and the heterocyclic moiety optionally further includes a second monovalent moiety that is an organic group containing 1 to 34 chain atoms, preferably carbon atoms, a beneficial agent fragment, and at least one of (a) at least one of the first monovalent moiety and, if present, the second monovalent moiety contains at least 5, preferably at least 8 chain atoms, preferably carbon atoms, and / or (b) the second monovalent moiety is present and the total number of chain atoms, preferably carbon chain atoms, in the first monovalent moiety and the second monovalent moiety is at least 8, applies to the pro-beneficial agent compound. B. The pro-beneficial agent compound according to paragraph A, wherein the carbon skeleton contains 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 carbon atom. C. The pro-beneficial agent compound according to paragraph A or B, wherein the carbon-containing core is derived from an amino acid, preferably a proteinogenic amino acid, more preferably a proteinogenic amino acid selected from the group consisting of alanine, glycine, valine, phenylalanine, leucine, isoleucine, or combinations thereof, even more preferably a proteinogenic amino acid selected from the group consisting of alanine, glycine, or combinations thereof. D. At least one side group is a side group of a protein - constituting amino acid or a derivative thereof, preferably a side group of a protein - constituting amino acid selected from the group consisting of valine, phenylalanine, leucine, isoleucine, alanine, glycine, derivatives thereof, or combinations thereof, more preferably having the structure of alanine, glycine, derivatives thereof, or combinations thereof, the pro - beneficial agent compound according to any one of paragraphs A - C. E. The pro - beneficial agent compound according to any one of paragraphs A - D, wherein the carbonyl - containing moiety is an ester moiety. F. The pro - beneficial agent compound according to any one of paragraphs A - E, wherein at least one of the first monovalent moiety and the second monovalent moiety is an organic group containing about 8 to about 18 chain atoms, preferably about 8 to about 14 chain atoms, more preferably carbon chain atoms. G. The pro - beneficial agent compound according to any one of paragraphs A - F, wherein at least one of the first monovalent moiety and the second monovalent moiety is an unsubstituted organic group, an unbranched - chain organic group, or a combination thereof, preferably a combination thereof. H. The pro - beneficial agent compound according to any one of paragraphs A - G, wherein the beneficial agent fragment is derived from a beneficial agent containing an aldehyde moiety, preferably derived from a fragrance raw material containing an aldehyde moiety. I. The pro - beneficial agent compound according to any one of paragraphs A - H, wherein the beneficial agent fragment is derived from a beneficial agent containing a ketone moiety, preferably derived from a fragrance raw material containing a ketone moiety. J. The pro - beneficial agent compound according to any one of paragraphs A - I, wherein the beneficial agent fragment is derived from a beneficial agent selected from fragrance raw materials, antibacterial agents, pesticides, insect repellents, antifungal agents, herbicides, hue dyes, antioxidants, non - fragrance sensory stimulants, or combinations thereof, preferably fragrance raw materials, antibacterial agents, or combinations thereof. K. The beneficial agent is a fragrance raw material, preferably selected from the group consisting of methyl nonyl acetaldehyde, benzaldehyde, floralozone; isocyclocitral, triplal (ligustral), precymon B, lilial; decyl aldehyde, undecylenic aldehyde, cyclamen homaldehyde, cyclamen aldehyde, dupical, oncidal, adoxal; melonal; calypsone; anisaldehyde, heliotropin; cumin aldehyde, scentenal; 3,6-dimethylcyclohex-3-ene-1-carbaldehyde, satenal, canthoxal; vanillin, ethyl vanillin, cinnamic aldehyde; cis-4-decenal, trans-4-decenal, cis-7-decenal, undecylenic aldehyde, trans-2-hexenal; trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, floridol, butyl cinnamic aldehyde, limonellal, amyl cinnamic aldehyde, hexyl cinnamic aldehyde, citronellal; citral; cis-3-hexen-1-al, neral, 4-(4-methoxyphenyl)butan-2-one; 1-naphthalen-2-ylethanone, nectaryl, trimofix O, fluramon, δ-damascone, β-damascone, α-damascone, methyl ionone, 2-hexylcyclopenta-2-ene-1-one; galavascone, and mixtures thereof, more preferably methyl nonyl acetaldehyde, benzaldehyde, floralozone; isocyclocitral, triplal (ligustral), precymon B, lilial; decyl aldehyde, undecylenic aldehyde, cyclamen homaldehyde, cyclamen aldehyde, dupical, oncidal, adoxal; melonal; calypsone; anisaldehyde, heliotropin; cumin aldehyde, scentenal;3,6-dimethylcyclohex-3-ene-1-carbaldehyde, satenal, canthoxal; vanillin, ethylvanillin, cinnamaldehyde; cis-4-decenal, trans-4-decenal, cis-7-decenal, undecylenal, trans-2-hexenal; trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, florhydral, cyclamen, butylcinnamaldehyde, limonellal, amylcinnamaldehyde, hexylcinnamaldehyde, citronellal; citral; cis-3-hexen-1-al, and an aldehyde-containing perfume raw material selected from the group consisting of mixtures thereof, more preferably, at least one of the first monovalent moiety and the second monovalent moiety is an organic group containing about 8 to about 18 chain atoms, even more preferably, an organic group containing about 10 to about 18 chain atoms, preferably, the chain atoms are carbon atoms, the pro-beneficial agent compound described in any of paragraphs A to J.; L. The beneficial agent is an antibacterial agent, preferably an antibacterial agent selected from acetylacetone enolate, gossypol, nootkatone, or mixtures thereof, more preferably, at least one of the first monovalent moiety and the second monovalent moiety is an organic group containing about 6 to about 12 chain atoms, preferably, the chain atoms are carbon atoms, the pro-beneficial agent compound described in any one of paragraphs A to K. M. The beneficial agent compound is characterized by the structure according to formula II,

[0206]

Chemical formula

[0207]

Chemical formula

[0208]

Chemical formula

[0209] [Chemical formula] wherein Q, R 1 R 4 R 5 and R 6 are pro-beneficial agent compounds as described above, in any of paragraphs M - R. T. For formula II, Q is an organic group containing about 8 to about 18 chain atoms, preferably most or all of the chain atoms are carbon atoms, G = -O-, m = 1, R 1 has the structure of the side group of a proteinogenic amino acid, R 2 is -H, d = 2, each J = C(R 6 )2, preferably R 6 is hydrogen, G' = -O-, and Z is a flavor raw material, preferably a fragment of a flavor raw material containing an aldehyde moiety, the pro-beneficial agent compound according to any one of claims 13 - 19. U. Further comprising a second beneficial agent fragment, preferably characterized by the structure according to formula II, the second beneficial agent fragment being part of the group consisting of Q, R 1 R 2 or R 6 the pro-beneficial agent compound according to any one of paragraphs A - T. V. A treatment composition comprising an auxiliary component and the pro-beneficial agent compound according to any one of paragraphs A - U. The treatment composition according to paragraph V, wherein the auxiliary component comprises one or more of a surfactant, a conditioning active substance, an adhesion aid, a rheology modifier or structuring agent, a bleaching system, an antioxidant, a stabilizer, a builder, a chelating agent, a migration inhibitor, a dispersant, an enzyme, an enzyme stabilizer, a catalytic metal complex, a polymer dispersant, a soil and stain removal / redeposition inhibitor, a brightening agent, a foam inhibitor, a silicone, a hue agent, an aesthetic dye, a pure fragrance, a fragrance delivery system, a structure elasticizer, a carrier, a hydrotrope, a processing aid, an antiagglomerant, a coating, a formaldehyde scavenger, and / or a pigment. X. The auxiliary component comprises a conditioning active substance, preferably the conditioning active substance comprises a quaternary ammonium ester compound, more preferably the quaternary ammonium ester compound is present in the treatment composition at a concentration of about 2% to about 35% by weight, preferably about 4% to about 25% by weight, more preferably about 5% to about 20% by weight, preferably about 6% to about 15% by weight, more preferably about 7% to about 12% by weight of the treatment composition, the treatment composition according to either paragraph V or W. Y. The treatment composition according to any one of paragraphs V to X, further comprising a pure fragrance, preferably a pure fragrance comprising an alcohol-containing fragrance raw material. Z. The composition according to any one of paragraphs V to Y, wherein the treatment composition is a consumer product, preferably a consumer product selected from the group consisting of a fabric care composition, a hard surface cleaner composition, a dish care composition, a hair care composition, a body cleansing composition, or a mixture thereof. AA. The treatment composition according to any one of paragraphs V to Z, which is in the form of a liquid composition, a granular composition, a hydrocolloid, a single-compartment pouch, a multi-compartment pouch, a soluble sheet, a pastille or bead, a fibrous article, a tablet, a stick, a bar, a flake, a foam or mousse, a non-woven sheet, or a mixture thereof. BB. The treatment composition according to any one of paragraphs V to AA, wherein the pro-beneficial agent compound is present in the treatment composition at a concentration of about 0.001% to about 30% by weight of the treatment composition. CC. The precursor compound is characterized by the structure according to formula VII.

[0210] [Chemical formula] In the formula, the group, and the subscript are as defined above, the pro-beneficial agent precursor compound. DD. A premix composition containing a pro-beneficial agent precursor compound, wherein the precursor compound is characterized by the structure according to formula VII,

[0211] [Chemical formula] In the formula, the group and the subscript are as defined above, the beneficial agent contains an aldehyde moiety, a ketone moiety, or a combination thereof, and the pro-beneficial agent precursor compound and the beneficial agent may optionally react to form a pro-beneficial agent compound described in any of paragraphs A to U. The total weight percentage of the pro-beneficial agent precursor compound, the beneficial agent, and the pro-beneficial agent compound (if present) is about 10 wt% to about 100 wt% of the premix composition, preferably about 25 wt% to about 100 wt%, more preferably about 50 wt% to about 100 wt%, even more preferably about 75 wt% to about 100 wt%, the premix composition. EE1. The premix composition according to paragraph DD, wherein the premix composition further contains water, preferably the premix composition is in the form of an emulsion, more preferably an oil-in-water emulsion. EE2. The premix composition according to paragraph DD, wherein the premix composition contains less than about 10 wt%, preferably less than 5 wt%, more preferably less than 1 wt%, even more preferably less than 0.1 wt% of water of the premix composition. FF. The molar ratio of the pro-beneficial agent precursor compound to the beneficial agent is about 3:1 to about 1:3, preferably about 2:1 to about 1:2, more preferably about 1.5:1 to about 1:1.5, more preferably about 1.2:1 to about 1:1.2, even more preferably about 1:1, the premix composition according to any one of paragraphs DD or EE. A method for preparing a treatment composition according to any one of paragraphs V to BB, comprising at least one of: (a) mixing a pro-beneficial agent compound with an auxiliary component, preferably, the auxiliary component is part of the base composition; (b) mixing a premix composition according to any one of paragraphs DD to FF with an auxiliary component, preferably, the auxiliary component is part of the base composition; (c) mixing a pro-beneficial agent precursor compound, a beneficial agent, and an auxiliary component, preferably, the auxiliary component is part of the base composition, and the pro-beneficial agent precursor compound and the beneficial agent are added to the base composition as separate inputs respectively. HH. A method for treating an article or a surface, comprising treating the article or the surface with a treatment composition according to any one of claims V to BB, optionally in the presence of water, and optionally further comprising the steps of rinsing and / or drying the article or the surface.

[0212] Test method Preparation of a premix fluid (e.g., waterless) The premix fluid can be prepared as follows. Method A: Add a beneficial agent containing an aldehyde or ketone moiety in a molar equivalent approximately equal to the molar concentration of the amine radical present in the precursor compound (e.g., the precursor compound of formula I above). Stir this substance at 150 rpm for at least 12 hours using a magnetic stir bar. Method B: Add a beneficial agent containing an aldehyde or ketone moiety in a molar equivalent approximately equal to the molar concentration of the amine radical present in the precursor compound (e.g., the precursor compound of formula VII above). Stir this material at 150 rpm for at least 12 hours using a magnetic stir bar in the presence of a water scavenger. The resulting fluid can be mechanically filtered or added directly to the treatment composition.

[0213] As an illustrative example, using an IKA RW20DS1 mixer, model RW20DS1, and an IKA R 1 342 impeller blade at 350 rpm, 59 parts by weight of a modified amino acid as disclosed in Synthesis Example 3 below is mixed with 41 parts by weight of a beneficial agent (e.g., cyclamen aldehyde).

[0214] Preparation of a premix emulsion (e.g., with water) The premix emulsion can be prepared as follows. Method A: Starting from 1 part by weight of the premix fluid provided in the previous example, diethylene glycol monobutyl ether (10.0 parts, TCI) and ECOSURF™ EH-9 (1 part, The Dow Chemical Company) are added. The mixture is added to a Flacktek DA150.FVZ-K high-speed mixer at 3,500 rpm for 1 minute. Water (88 parts in total) is added in two portions, and after each addition of water, the mixture is mixed at 3,500 rpm for 10 - 15 minutes using a Flacktek Da150.FVZ-K high-speed mixer. Method B: Starting from 1 part by weight of a precursor compound (e.g., a hydrophobic modified amino acid), diethylene glycol monobutyl ether (10.0 parts; TCI) and ECOSURF™ EH-9 (1 part, The Dow Chemical Company) are added. The mixture is added to a Flacktek DA150.FVZ-K high-speed mixer at 3,500 rpm for 1 minute. Water (88 parts in total) is added in two portions, and after each addition of water, the mixture is mixed at 3,500 rpm for 10 - 15 minutes using a Flacktek Da150.FVZ-K high-speed mixer. The beneficial agent is added in a molar equivalent approximately equal to the molar concentration of the amine radicals present in the precursor compound.

[0215] As an illustrative example, 99 parts by weight of an emulsified fluid containing a modified amino acid as disclosed in Synthesis Example 3 below (containing approximately 1 part by weight of the modified amino acid) emulsified as described above is mixed with 1 part by weight of a beneficial agent (e.g., cyclamen aldehyde).

[0216] Preparation of Test Fabric Softener / Softening Agent Composition Provide 7.5 wt% of N,N - bis(tallow oil oxyethyl)-N,N - dimethylammonium chloride in an aqueous mixture. Add the above - mentioned premix fluid, the above - mentioned premix emulsion, or two separate pure fluids (one is a pro - benefit agent precursor such as a modified amino acid and the other is a benefit agent such as one or more fragrance raw materials) so that the concentration of the benefit agent or benefit substance fragment in the fabric softener is about 0.3 wt% of the final fabric softening agent composition. Stir the mixture at 350 rpm for 5 minutes using an IKA RW20DS1 mixer, model RW20DS1, and an IKA RI342 impeller blade. Add a structuring agent and an adhesion aid and stir the mixture for 10 minutes. Add water as needed to normalize the concentration of N,N - bis(tallow oil oxyethyl)-N,N - dimethylammonium chloride between test legs to 7.3 wt% and stir the mixture for 5 minutes. Adjust the pH to 2 - 3 with 1N HCl as needed.

[0217] Preparation of Test Pastille Composition Add a mixture of 98.01 parts by weight of molten PEG - 8000 material and 0.59 parts by weight of the pro - benefit agent premix fluid of Synthesis Example 1 to a high - speed mixer cup. Quickly place the high - speed mixer cup in a Flacktek DA150.FVZ - K high - speed mixer at 3500 rpm for 1 minute. Pour into a blue silicone - treated rubber mold pre - equilibrated at 4°C and spread with a 10” plastic taping knife to immediately produce sample pastilles from the mixture. Cool the pastilles at room temperature for about 30 minutes, then remove the pastilles from the mold and store under ambient conditions.

[0218] Preparation of Test Fabric Detergent Composition To 97.58 parts by weight of TIDE Original Scent liquid detergent, 2.42 parts by weight of the pro-beneficial agent-compound premix fluid of Synthesis Example 3B is added. The amount is selected such that the concentration of the selected beneficial agent or beneficial substance fragment in the final detergent is about 1% by weight after the fabric treatment composition. Using an IKA RW20DS1 mixer, model RW20DS1, and an IKA RI342 impeller blade, the mixture is stirred at 350 rpm for 10 minutes.

[0219] Preparation of Liquid Dishwashing Detergent 0.6 part by weight of the pro-beneficial agent compound premix fluid is added to 99.4 parts by weight of Ultra Dawn Blue Diswashing Liquid. The pro-beneficial agent amino acid ester is added in an amount such that the concentration of the beneficial agent or beneficial substance fragment in the dishwashing liquid is about 0.2% by weight after composition. The mixture is mixed on a Thermo Scientific Tube Roller, Model No. 88881003 at 80 rpm for 1 hour.

[0220] Method for Preparing Fabric To prepare fabric for headspace analysis testing, a fabric sample (100% cotton terry cloth, item number ITL 1022-15PGP, Calderon Textiles, Inc. 6131 W. 80th A St., Indianapolis, Ind. 46278, desized and conditioned with three wash cycles of detergent and fabric softener) is treated with a detergent or fabric conditioner in a manner consistent with North American consumers via a mini-clothes washer, full-scale machine, and clothes dryer. Unless otherwise stated, the fabric is equilibrated at 21.1 °C and 50% relative humidity for 24 hours prior to headspace GCMS analysis (see the following method). The ballast load consists of samples of cotton and polycotton knit of approximately 20 × 20 inch (50 × 50 cm) size.

[0221] Washing Treatment Conditions In the following fabric strengthening agent / softening agent composition performance test, the fabric is treated under the following washing conditions. Washing: Stir for 12 minutes, 30.6 °C, Rinsing: Stir for 2 minutes, 15.5 °C, Water hardness: 137 ppm, Water: 7.6 pH, Fabric load weight: 290 g, Tumbler drying setting: High for 50 minutes, Cotton, Detergent dosage: 9.65 g, Fabric softener dosage: 5.71 g.

[0222] In the following pastille composition performance test, the fabric is treated under the following washing conditions. A North America Kenmore 600 series vertical washing machine is used. Each machine is set to perform a normal single cycle including a 12-minute washing agitation period and one 3-minute rinse. The water used has a hardness of 137 ppm, is at 30.6 °C for each wash, and 15.5 °C for the rinse. The volume of water in each process is 64 liters. The total fabric load weight is 3.6 kg (including 32 test fabric hand towels, 9 pieces of 100% cotton ballast, and approximately 5 pieces of 50 / 50 polycotton ballast). The detergent used was fragrance-free liquid TIDE Original Scent (manufactured by The Procter & Gamble Company). While the wash water is being filled, 81 g of the detergent is added to the wash water. Also, after adding the detergent, 25 g of the pastille to be evaluated is added, followed by the fabric. When the water filling is complete, the machine enters the immersion period. This is followed by the washing agitation (normal setting) and the rinse process (with the corresponding spin cycle). When the washing process is complete, the fabric is removed. The test fabric is machine dried for 50 minutes in a Kenmore dryer set to cotton / high, or the test fabric is line dried for 16 hours in a room controlled at 21.1 °C / relative humidity 50%.

[0223] In the following detergent composition performance test, the fabric is treated under the following washing conditions. Washing: Stir for 12 minutes, 30.6 °C, Rinsing: Stir for 2 minutes, 15.5 °C, Water hardness: 137 ppm, Water: 7.6 pH, Fabric load weight: 290 g, Tumbler drying setting: High for 50 minutes, Cotton, Detergent dosage: 9.65 g, Fabric softener dosage: 5.71 g.

[0224] Headspace analysis of the fabric In the following procedure, the level of the beneficial agent in the headspace on the fabric is determined.

[0225] Gas chromatograph 7890B equipped with a mass selective detector (5977B) (MSD) and a ChemStation quantitative package, Gerstel multipurpose sampler equipped with a solid phase microextraction (SPME) probe or a similar system, divinylbenzene / Carboxen / polydimethylsiloxane SPME fiber from Supleco part #57298-U (or a similar fiber), nominal diameter 30m × 0.25mm, film thickness 0.25m, J&W 122-5532UI DB-5, 20mL headspace vial.

[0226] To prepare the fabric for analysis, cut three 2.54 cm × 5.08 cm cotton samples from the cotton terry prepared and treated by the above method. Place each piece into a 20 mL headspace vial and cap.

[0227] The parameters of the Gerstel autosampler are as follows: from SPME-incubator, incubation temperature - 65°C, incubation time - 10.00 minutes sample parameters, vial penetration - 22.00 mm, extraction time - 5.00 minutes, initial penetration - 54.00 mm, desorption time - 300 seconds. The parameters of the GC oven are as follows: for front SS inlet He, mode - splitless, heater - 270°C, GC operation time - 14.28 minutes. For the oven, initial temperature - 40°C, hold time - 0.5 minutes, heating program - at a rate of 17°C / minute, temperature of 270°C, hold time of 0.25 minutes. The MSD parameters are as follows. In scan mode, run with a minimum range of 35 - 350 m / z.

[0228] Generate a calibration curve from the standard beneficial agent material. Use the calibration curve of each fragrance component with ChemStation software (or similar quantitative software) to calculate the mass in the headspace.

[0229] Color change of the composition The treatment composition may be tested for color change according to the following procedure. L * , a * , and b * The reflectance spectrum and color measurements including them were made using a LabScan XE reflectance spectrophotometer (Hunter Labs, Reston, VA; D65 light source, 10-degree field of view, excluding ultraviolet light). L * , a * , and b * values are at time t initial , i.e., at the start of the test after mixing in the beneficial agent, and t final , i.e., measured at the end of the stability test defined in each experiment. The total color change (ΔE) of the treatment composition is calculated based on the data collected at each time point t using the following formula. ΔE t =((L * c -L * s ) 2 +(a * c -a * s ) 2 +(b * c -b * s ) 2 ) 1 / 2 In the formula, the subscripts c and s refer to the control, i.e., the treatment composition with nil beneficial agent, and the sample, i.e., the treatment composition with each aldehyde / ketone beneficial agent, respectively, and the values used to calculate ΔE t are the values at the corresponding time points t initial and t final .

[0230] Samples were prepared by adding a professional beneficial agent fluid premix (without water) to the base treatment composition while overhead mixing using a 4-blade IKA RW20 impeller and gently mixing for 15 minutes. The treatment composition was placed in a 50 mL (25 cm 2)Place it in a CELLSTAR (registered trademark) cell culture flask. At a specific temperature t initial and after t final time, measure the color appearance of each treatment composition sample on a LabScan XE 10 reflectance spectrophotometer (Hunter Labs, Reston, VA; B.; D65 light source, 10-degree field of view, excluding ultraviolet light).

[0231] HLB value of nonionic surfactant Nonionic surfactants can be classified by the balance between the hydrophilic and lipophilic parts in the surfactant molecule. The hydrophilic-lipophilic balance (HLB) scale devised by Griffin in 1949 is a scale from 0 to 20 (20 being hydrophilic) used to characterize the properties of surfactants. The HLB of a surfactant can be calculated as follows: HLB = 20 * Mh / M (where Mh is the molecular weight of the hydrophilic part of the molecule and M is the molecular weight of the whole molecule, and the result is given on a scale of 0 to 20). An HLB value of 0 corresponds to a completely lipophilic / hydrophobic molecule, and a value of 20 corresponds to a completely hydrophilic / lipophobic molecule. See Griffin, W. C. Calculation of HLB values of Nonionic Surfactants, J. Soc. Cosmet. Chem. 1954, 5, 249-256. The HLB values of commonly used surfactants are readily available from the literature (e.g., the HLB index in McCutcheon’s Emulsifiers and Detergents, MC Publishing Co., 2004). The HLB value of a mixture of surfactants can be calculated as the weighted average of the HLB values of the surfactants.

[0232] Test method for determining logP The value of the logarithm of the octanol / water partition coefficient (logP) is calculated for materials as described herein (such as hydrophobic substances / Q groups or alcohol versions of PRMs).

[0233] The logP values of the individual materials were calculated using the Consensus logP Computational Model, version 14.5 (Linux®), available from Advanced Chemistry Development Inc. (ACD / Lab) (Toronto, Canada), and unitless logP values were obtained. The ACD / Labs Consensus logP Computational Model is part of the ACD / Labs model suite.

Example

[0234] The examples provided below are in fact intended to be illustrative and not limiting.

[0235] Synthesis Example The following Synthesis Examples 1-7 illustrate the synthesis of exemplary pro-beneficial agent compounds (e.g., Synthesis Example 1) and their alkanolamine-containing precursors (e.g., Synthesis Example 1')) according to the present disclosure.

[0236] Comparative Synthesis Example A shows a comparative modified amino acid ester. Comparative Synthesis Example A interacts with an aldehyde via an imine moiety, which is chemically different from the heterocyclic-forming substances described herein.

[0237] For consistency and illustrative / comparative purposes, each example reacts a different pure pro-beneficial agent precursor compound with the same flavor raw material precitremone B (containing a quaternary α-carbon aldehyde moiety) having the structure provided below. As additional examples, Synthesis Examples 2B, 3, and 4 form pro-beneficial agent compounds with cyclamen aldehyde containing a tertiary α-carbon aldehyde moiety. The structure of the PRM is shown below.

[0238]

Chemical Formula

[0239] However, it is understood that other aldehyde- or ketone-containing beneficial agents according to the present disclosure may also result in the formation of suitable pro-beneficial agent compounds. Some of these are illustrated and tested in the performance examples below.

[0240] It is also understood that the synthesis examples may be incorporated into the treatment composition as a liquid premix emulsion, or as a pure fluid, or as a liquid premix fluid as described above. However, for the performance and stability examples reported below, all synthesis examples are assumed to be incorporated directly as a liquid premix fluid into the treatment composition unless otherwise indicated.

[0241] For each synthesis example, the resulting pro-beneficial agent compound (e.g., modified alkanolamine amino acid ester) is shown together with pre-cyclomone B (or in the case of Synthesis Examples 2B, 3, and 4, cyclamen aldehyde) and provided in Table D below. Comparative Synthesis Example A, which is a modified amino acid ester, is illustrated with cinnamaldehyde in Table D but does not contain a heterocyclic-forming pro-beneficial modified amino acid ester.

[0242] Method for preparing pro-beneficial agent compounds (e.g., modified amino acid esters) In the following synthesis examples, materials are generally obtained / available from Sigma-Aldrich (St. Louis, Missouri, USA) unless otherwise indicated below. Amino acids are generally provided with a purity of greater than 98% or even greater than 99%. Alcohols are generally provided with a purity of greater than 97%, greater than 98%, or even greater than 99%. Cyclamen aldehyde and cinnamaldehyde (e.g., Sigma-Aldrich) are provided with a purity of greater than 95%. Pre-cyclomone B is available from IFF, New York, NY.

[0243] General Method A: General preparation of amino acid ester precursor compounds To prepare an amino acid ester compound from an amino acid and an alkyl alcohol, a round-bottom flask is charged with 1 equivalent of the free base amino acid starting material. 1 equivalent of the selected alcohol reagent is added to the flask, followed by 1.2 equivalents of p-toluene-sulfonic acid monohydrate (PTSA). The contents of the flask are then diluted with toluene and refluxed for 12 hours using a Dean-Stark apparatus. The toluene is then removed under vacuum, and the resulting crude material is dissolved in chloroform. The solution is neutralized with Et3N, washed three times with NaHCO3, and dried over anhydrous MgSO4. The residual solvent is removed, the washed material is diluted with cyclohexane, and then stored at 0 °C for at least 12 hours. The eluate is collected to obtain the desired modified amino acid ester.

[0244] General Method B: General Preparation of Pro-Beneficial Agent Precursor Compounds (e.g., Alkanolamine-Modified Amino Acid Esters) A round-bottom flask is charged with 1 equivalent of an amino acid ester precursor (such as those generally described in General Method A or from a commercial source). 1.2 equivalents of the target oxirane material and 20 wt% trifluoroethanol are added to the flask. The resulting mixture is refluxed for at least 8 hours. After cooling, the solvent is removed. The resulting material is then further purified by silica gel chromatography using a stepwise elution of EtOAc to hexane (V / V) from 1:15 to 1:4.

[0245] General Method C: General Preparation of Pro-Beneficial Agent Compounds A round-bottom flask is charged with 1 equivalent of an alkanolamine-modified amino acid precursor (such as those generally described in General Method B). 1 equivalent of either cyclamen aldehyde or precymene B is added to the flask. 20 wt% of 4 Å molecular sieves are added to the mixture, and the mixture is stirred for 12 hours. The resulting mixture is filtered using a Pyrex 36060-30M Brand 36060 frit funnel and used directly.

[0246] Comparative Synthesis Example A * Comparative Synthesis Example A’ was prepared as described in General Method A, except that 10.0 g of L-valine, 16.1 g of 1-dodecanol, and 19.5 g of PTSA·H2O were used. * Next, the isolated fluid of Synthesis Example A’ * was mixed with cinnamaldehyde as described in General Method C, except that the alkanolamine amino acid precursor was replaced with the amino acid ester precursor obtained from General Method A. By the reaction, Comparative Synthesis Example A * was obtained. The independent fluid A * appears to be stable by 1H NMR for several months.

[0247] Synthesis Example 1 The first step was carried out as described in General Method A, except that 10.0 g of L-valine, 23.1 g of 1-octadecanol, and 19.5 g of PTSA.H2O were used. Then, Synthesis Example 1’ was prepared as described in General Method B, except that the substance obtained in the first step and 1.2 equivalents of propylene oxide were used. Next, the isolated precursor Synthesis Example 1’ was mixed with preciclomone B (IFF, New York, NY) as described in General Method C to obtain Synthesis Example 1’. The colorless independent fluid 1 appears to be stable by 1H NMR for several months.

[0248] Synthesis Example 2A To a solution of 10 g of L-valine ethyl ester hydrochloride (Sigma Aldrich, St. Louis, MO, USA) in 2.2 g of trifluoroethanol, 1 equivalent of Et3N was added. Then, Synthesis Example 2’ was prepared as described in General Method B, except that 1.2 equivalents of 1,2-epoxydodecane were used. Next, the isolated precursor Synthesis Example 2’ was mixed with preciclomone B (IFF, New York, NY) as described in General Method C to obtain Synthesis Example 2A. The colorless independent fluid 2A appears to be stable by 1H NMR for several months.

[0249] Synthesis Example 2B To a solution of 10 g of L-valine ethyl ester hydrochloride (Sigma Aldrich, St. Louis, Missouri, USA) in 2.2 g of trifluoroethanol, 1 equivalent of Et3N is added. Next, Synthesis Example 2’ was prepared as described in General Method B, except that 1.2 equivalents of 1,2-epoxydodecane were used. Then, the isolated precursor Synthesis Example 2’ was mixed with a cyclamen aldehyde (Sigma Aldrich, St. Louis, Missouri, USA) as described in General Method C to obtain Synthesis Example 2B. The colorless, independent fluid 2B appears to be stable by 1H NMR for several months.

[0250] Synthesis Example 3 The first step was carried out as described in General Method A, except that 10.0 g of L-valine, 16.1 g of 1-dodecanol, and 19.5 g of PTSA·H2O were used. Next, Synthesis Example 3’ was prepared as described in General Method B, except that the substance obtained in the first step and 1.2 equivalents of butyl glycidyl ether were used. Then, the isolated precursor Synthesis Example 3’ was mixed with a cyclamen aldehyde (Sigma Aldrich, St. Louis, Missouri, USA) as described in General Method C to obtain Synthesis Example 3. The colorless, independent fluid 3 appears to be stable by 1H NMR for several months.

[0251] Synthesis Example 4 The first step was carried out as described in General Method A, except that 10.0 g of L-valine, 16.1 g of 1-dodecanol, and 19.5 g of PTSA·H2O were used. Next, Synthesis Example 4’ was prepared as described in General Method B, except that the substance obtained in the first step and 1.2 equivalents of propylene oxide were used. Then, the isolated precursor Synthesis Example 4’ was mixed with a cyclamen aldehyde (Sigma Aldrich, St. Louis, Missouri, USA) as described in General Method C to obtain Synthesis Example 4. The colorless, independent fluid 4 appears to be stable by 1H NMR for several months.

[0252] Synthesis Example 5 To a solution of 10 g of L-alanine ethyl ester hydrochloride (Sigma Aldrich, St. Louis, Missouri, USA) in 2.2 g of trifluoroethanol, 1 equivalent of Et3N was added. Next, Synthesis Example 5’ was prepared as described in General Method B, except that 1.2 equivalents of 1,2-epoxydodecane were used. Then, the isolated precursor Synthesis Example 5’ was mixed with preciclopremone B (IFF, New York, NY) as described in General Method C to obtain Synthesis Example 5. The colorless, independent fluid 5 appears to be stable by 1H NMR for several months.

[0253] Synthesis Example 6 The first step was carried out as described in General Method A, except that 10.0 g of L-valine, 11.1 g of 1-octanol, and 19.5 g of PTSA·H2O were used. Next, Synthesis Example 6’ was prepared as described in General Method B, except that the substance obtained in the first step and 1.2 equivalents of butyl glycidyl ether were used. Then, the isolated precursor Synthesis Example 6’ was mixed with preciclopremone B (IFF, New York, NY) as described in General Method C to obtain Synthesis Example 6. The colorless, independent fluid 6 appears to be stable by 1H NMR for several months.

[0254] Synthesis Example 7 The first step was carried out as described in General Method A, except that 10.0 g of L-valine, 11.1 g of 1-octanol, and 19.5 g of PTSA·H2O were used. Next, Synthesis Example 7’ was prepared as described in General Method B, except that the substance obtained in the first step and 1.2 equivalents of propylene oxide were used. Then, the isolated precursor Synthesis Example 7’ was mixed with preciclopremone B (IFF, New York, NY) as described in General Method C to obtain Synthesis Example 7. The colorless, independent fluid 7 appears to be stable by 1H NMR for several months.

[0255] Structure of Synthesis Examples Table D below shows the structures of Synthesis Examples 1 - 7, as well as their precursor compounds (indicated by “ ’ ”).

[0256] Table D also includes Comparative Synthesis Example A as a precursor * , and Comparative Synthesis Example A of a modified amino acid ester containing an imine bond * . Comparative examples are marked with an asterisk ( * ).

[0257]

Table 5-1

[0258]

Table 5-2

[0259] In the following Performance Examples and Stability Examples, the heterocyclic pro-beneficial agent precursor compounds (e.g., alkanolamine-modified amino acid ester molecules) and the indicated fragrance raw materials are mixed substantially according to the procedure found in the above test method section ("Preparation of the Premix Fluid"). Despite the different preparation methods between the single PRM fragment of the Synthesis Example and the single PRM fragment of the Performance and Stability Examples, the inputs and outputs for the heterocyclic pro-beneficial agent compounds are substantially the same.

[0260] Performance Examples In the following Performance Examples 1 to 4, treatment compositions containing neat oils, or heterocyclic pro-beneficial agent compounds according to the present disclosure (e.g., based on alkanolamine-modified amino acid esters), or premix emulsions containing comparative modified amino acid esters, are compared via a treatment cycle in an automatic washing machine according to the above fabric treatment method. After treatment, the fabric is tested for headspace analysis by the test method provided above. The following data show the benefits provided by the hydrophobic modified amino acid esters and their interactions with the beneficial agents via the heterocyclic rings in delivering the beneficial agents.

[0261] Performance Example 1. Advantages in Dry Particle Formulations First, Synthesis Example 1' is reacted with the aldehyde formulation as described above to obtain a structure similar to that of Synthesis Example 1, but is replaced with a fragment of the aldehyde code to which a fragment of precymon B is added. In this example, the formulation of the material is adjusted for dry-formed particle applications (e.g., a pastille containing polyethylene glycol as a carrier, similar in size and shape to those sold as DOWNY UNSTOPABLES™ by Procter & Gamble Company). The formulation of the particles for each leg is presented in Table 1A, where Synthesis Example 1 is introduced as a premix fluid as detailed above. The amounts are shown as weight % of the composition.

[0262]

Table 6

[0263] In the following examples, the premix material of Synthesis Example 1 is provided to a test fabric tablet composition prepared as provided by the above test method. The test fabric is prepared, washed, and tested for headspace analysis on the dried fabric according to the above test method. The performance test results are presented in Table 1B.

[0264]

Table 7

[0265] As shown in Table 1B, Synthesis Example 1 in the dry particle formulation shows advantages over the pure raw material through rinsing and the dryer.

[0266] Performance Example 2. Advantages in Liquid Fabric Strengthening Agent Combinations Heterocyclic pro-beneficial modified amino acid Synthesis Example 2A was tested in a liquid fabric strengthening agent combination. In the following examples, an equimolar concentration of aldehyde beneficial agent described in each test leg was provided to the precursor alkanolamine amino acid as described above, and then incorporated into the test fabric strengthening agent / softening agent composition prepared as provided in the above test method. Test fabrics were prepared, washed, and tested for headspace analysis on the fabric according to the above test method.

[0267] The results of the headspace analysis test on the fabric are presented in Table 2A below.

[0268] [Table 8] α The beneficial combination is 0.2 wt% of precitremon B.

[0269] As shown in Table 2A, the heterocyclic-forming modified amino acid ester 2A resulted in an improvement in the total headspace compared to the pure raw material.

[0270] Performance Example 3. Effect of Monovalent Moieties To further evaluate these materials, sterically unhindered aldehyde materials were tested. In the following examples, an equimolar concentration of cyclamen aldehyde described in each test leg was provided to Synthesis Examples 2B, 3, and 4 of the alkanolamine precursor amino acid as described above, and then incorporated into the test fabric strengthening agent / softening agent composition prepared as provided in the above test method.

[0271] For convenience, the structures of the first monovalent moiety (i.e., the moiety bonded to the core carbonyl moiety, the Q group) and the second monovalent moiety (i.e., the moiety bonded to the heterocyclic moiety, the R 6 group) are presented in Table 3A below, respectively. In the structures provided below, the symbol "#" indicates each bonding point.

[0272]

Table 9

[0273] Prepare the test fabric, perform a washing treatment, and test for headspace analysis on the fabric according to the above test method. Present the results of the headspace analysis test on the fabric in Table 3B below.

[0274]

Table 10

[0275] As shown in Table 3, alkanolamine-modified amino acid esters 2B, 3, and 4 resulted in an improvement in the total headspace compared to the pure raw materials.

[0276] Dodecyl ester amino acid materials 3 and 4 differ only by substitution on the heterocycle. Glycidyl ether construct 3 is relatively electron-deficient and delivered a higher headspace of cyclamen aldehyde through washing.

[0277] Furthermore, comparing 3 with Synthesis Example 2B suggests that the shortest ester bonded to the core in combination with a longer hydrophobic moiety on the heterocycle is the most preferred substitution pattern. Synthesis Example 2B based on amino acid valine ethyl ester had the highest total headspace in the series.

[0278] Performance Example 4. Comparison of steric hindrance (including different amino acid side chain groups) The effect of steric hindrance of the amino acid side chain was investigated in a liquid fabric formulation. In this example, various pro-beneficial agent compounds were tested.

[0279] In the following examples, equimolar concentrations of aldehyde benefit agents described in each test leg are provided to the above alkanolamine precursor amino acids and then incorporated into test fabric strengthening agent / softening agent compositions prepared as provided in the above test methods. Test fabrics are prepared, subjected to a washing treatment, and tested for headspace analysis on the fabric according to the above test methods.

[0280] (Non-hydrogen) side groups (R 1 ) of each test compound, a first monovalent moiety (Q), and a second monovalent moiety (R 6 ) are presented in Table 4A below. The symbol "#" indicates where the point of attachment is in the relative position.

[0281]

Table 11

[0282] In both Table 4B and subsequent tables, for rows written as "Synthesis Example 5" etc., the samples were prepared substantially according to the methods and precursors provided in the enumerated synthesis examples, but were prepared using not only cyclamen aldehyde or precymene B, but also benefit agent materials (in equimolar concentration relative to the precursor alkanolamine modified amino acid ester) listed in the performance table and formulated as a premix fluid as detailed above.

[0283] The results of the headspace analysis test on the fabric are presented in Table 4B below.

[0284]

Table 12

[0285] As exemplified in this example, the heterocyclic-modified alanine esters of Synthesis Examples 5, 6, and 7 provided an improvement in the overall headspace compared to those based on pure raw materials and valine ethyl ester (Synthesis Example 2). The improvement was particularly notable with the aldehyde raw materials P.T. businal and methyl nonyl acetaldehyde in Synthesis Examples 5, 6, and 7. Without wishing to be bound by theory, steric repulsion between the amino acid side chain group and the substitution of the α-carbon on the beneficial agent may potentially strongly affect performance.

[0286] As described in the previous performance examples, this test also suggests that ethyl ester (Synthesis Example 5) and glycidyl ether (Synthesis Example 6) amino acid constructs may be more preferred than Synthesis Example 7. This may be due to differences in hydrolysis rates based on the amount of hydrophobicity on the heterocyclic core, and the hydrophobicity around the heterocyclic ring may be more preferred than the hydrophobicity bonded to the carbonyl-containing portion of the amino acid ester.

[0287] Stability Example In Stability Example 1, a pro-beneficial agent compound (e.g., modified amino acid ester) in a premix fluid is incorporated into the treatment composition, and the color stability during storage is recorded.

[0288] Color Stability in the Liquid Treatment Composition of Stability Example 1 A premix in fluid form containing a heterocyclic-forming pro-beneficial agent precursor (e.g., modified amino acid ester) and a fragrance raw material, and related fabric softener products formed from such a premix fluid are prepared. Color measurements of fabric softener products containing the premix fluid (or pure PRM) are measured as described in the above test method. A relatively low ΔE t value indicates relatively little color change compared to the fresh product.

[0289] The aldehyde-containing beneficial agent is formulated at 0.2% by weight of the total treatment composition. The aldehyde-based fragrance composition is as follows: 10% by weight of methyl nonyl acetaldehyde, 35% by weight of P.T. businal, 20% by weight of precyclocremon B, 30% by weight of florozone, and 5% by weight of cinnamaldehyde). Similar to the previous examples, the synthesis examples are prepared using the listed aldehydes instead of simply cyclamen aldehyde or precyclocremon B and reacted with precursor compounds in the form of a premix fluid as detailed above (e.g., synthesis example 2’). A comparative composition is prepared using a modified amino acid ester and the same aldehydes as above (e.g., comparative example A * ).

[0290] The color stability of the fabric softener product when stored for one week is evaluated by the color change of the above composition test method. The results are shown in Table S1 below.

[0291]

Table 13

[0292] As shown in Table S1, the product formulated using synthesis example 2 containing a heterocyclic-forming modified amino acid ester in combination with a beneficial agent fragment shows a ΔE t similar to that of the product formed using the pure raw materials.

[0293] Furthermore, the product formulated using synthesis example 2 shows a relatively lower ΔE * compared to the product formulated using the imine-containing modified amino acid ester of comparative synthesis example A t after storage at 50°C. Without being bound by theory, the π bond is in comparative synthesis example A *It is highly likely to be the cause of the color intensity of the imine represented by . The influence of π-bond conjugation is further emphasized using cinnamaldehyde, and the extended conjugation during imine formation results in visible wavelength coloring. Additionally or alternatively, the nature of the bonds in the heterocycle results in the elimination of static π-bonds, leading to the heterocyclic moiety of Synthesis Example 2, and is considered to result in improved color stability over time due to a decrease in conjugation and a decrease in condensation side reactions.

[0294] The dimensions and values disclosed herein should not be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise indicated, each such dimension is intended to mean both the recited value and the functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" shall be taken to mean "about 40 mm".

[0295] All documents cited herein, including any patents or patent applications that are cross-referenced or related, and any patent application or patent for which this application claims priority or the benefit thereof, are hereby incorporated by reference in their entirety, unless expressly excluded or limited. The citation of any document shall not be construed as an admission that such document is prior art with respect to any invention disclosed or claimed herein, or that it alone, or in combination with any other reference(s), teaches, suggests, or discloses any such invention. Further, in the event that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition given to the term in this document shall apply.

[0296] Although specific embodiments of the present invention have been illustrated and described, it will be apparent to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the present invention. Accordingly, all such changes and modifications within the scope of the present invention are intended to be encompassed by the appended claims.

Claims

1. A treatment composition comprising an auxiliary component and a beneficial agent precursor compound, wherein the beneficial agent is an aldehyde-containing fragrance raw material, the beneficial agent precursor compound is characterized by a structure according to Formula II, 【Chemical 1】 wherein the subscript m is selected from 1 to 6, the subscript d is selected from 1 to 3, G and G' are both -O-, Q contains 1 to 34 chain atoms, and the chain atoms are carbon atoms, wherein R １ and R ２ are each independently selected from -H or a monovalent moiety having a molecular weight of 15 to 1000 Da, Z is a beneficial agent fragment consisting of the carbon atom and hydrogen atom of the aldehyde group of the aldehyde-containing fragrance raw material and the fragrance raw material part other than the aldehyde group, Each J is C(R ６ ) ２ and Each R ６ is independently selected from a hydrocarbon group having a molecular weight of H, 14 to 990 Da or a hydrocarbon group having an ether moiety, the treatment composition is a consumer product selected from the group consisting of a fabric care composition, a hard surface cleaner composition, a dish care composition, a hair care composition, and a body cleansing composition.

2. Q contains at least eight chain atoms, and R ６ is a processing composition according to claim 1, which contains no more than four chain atoms.

3. At least one R ６ The treatment composition according to claim 1, wherein R contains at least 8 chain atoms and Q contains 1 to 4 chain atoms.

4. At least one R １ or R ２ is the treatment composition according to claim 1, having the structure of the side chain of a protein constituent amino acid.

5. The beneficial agent precursor compound is characterized by a structure according to Formula IV, 【Chemical 2】 wherein Q contains 1 to 34 chain atoms, and the chain atoms are carbon, R １ is selected from -H or a monovalent moiety having a molecular weight of 15 to 1000 Da, R ４ is the fragrance raw material part other than the aldehyde group of the aldehyde-containing fragrance raw material, R ５ is -H, G' is -O-, and Each J is C(R ６ ) ２ and Each R ６ is independently selected from a hydrocarbon group having a molecular weight of H, 14 to 990 Da or a hydrocarbon group having an ether moiety, the treatment composition according to claim 1.

6. The beneficial agent precursor compound is characterized by a structure according to Formula V, [Chemical Formula 3] wherein Q contains 1 to 34 chain atoms, and the chain atoms are carbon, R １ is selected from -H or a monovalent moiety having a molecular weight of 15 to 1000 Da, R ４ is the part of the fragrance raw material other than the aldehyde group of the aldehyde-containing fragrance raw material, R ５ is -H, and Each R ６ is independently selected from a hydrocarbon group having a molecular weight of H, 14 to 990 Da or a hydrocarbon group having an ether moiety, the treatment composition according to claim 1.

7. Regarding Formula II, Q is an organic group containing 8 to 18 carbon atoms, m = 1, R １ has the structure of the side group of the protein constituent amino acid, R ２ is -H, d = 2, the treatment composition according to Claim 1.

8. The aldehyde-containing perfume raw material is selected from the group consisting of 2-methylundecanal, benzaldehyde, 3-(4-ethylphenyl)-2,2-dimethylpropanal; 2,4,6-trimethyl-3-cyclohexene-1-carboxaldehyde, 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, 1-methyl-3-(4-methylpenta-3-enyl)cyclohex-3-ene-1-carbaldehyde; 3-(4-tert-butylphenyl)butanal; decyl aldehyde, undecylenic aldehyde, 2-methyl-3-[4-(2-methylpropyl)phenyl]propanal; α-methyl-4-(1-methylethyl)-benzene propanal, 4-(octahydro-4,7-methano-5H-indene-5-ylidene)butanal, 2,6,10-trimethyl-5,9-undecadienal, 2,6,10-trimethylundec-9-enal; 2,6-dimethyl-5-heptenal; 6-methoxy-2,6-dimethyloctanal; 4-methoxy-benzaldehyde, 1,3-benzodioxole-5-carboxaldehyde, 4-propan-2-ylbenzaldehyde, 6-methoxydicyclopentadiene carboxaldehyde, 3,6-dimethylcyclohex-3-ene-1-carbaldehyde, 2-methyl-3-(4-methoxyphenyl)propanal, 4-methoxy-α-methyl-benzene propanal; 4-hydroxy-3-methoxybenzaldehyde, 3-ethoxy-4-hydroxybenzaldehyde, cinnamic aldehyde, cis-4-decenal, trans-4-decenal, cis-7-decenal, undecylenic aldehyde, trans-2-hexenal; trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, β-methyl-3-(1-methylethyl)-benzene propanal, 3-(4-isopropylphenyl)-2-methylpropanal, butyl cinnamaldehyde; β-4-dimethylcyclohex-3-ene-1-propane-1-al, amyl cinnamaldehyde; hexyl cinnamaldehyde, 3,7-dimethyl-6-octanal, 3,7-dimethyl-2,6-octadienal, cis-3-hexen-1-al, and mixtures thereof, and the treatment composition according to claim 1.

9. The auxiliary component(s) of the treatment composition according to claim 1 comprises one or more of a surfactant, a conditioning active substance, an adhesion aid, a rheology modifier or structuring agent, a bleaching system, an antioxidant, a stabilizer, a builder, a chelating agent, a migration inhibitor, a dispersant, an enzyme, an enzyme stabilizer, a catalytic metal complex, a polymeric dispersant, a soil and stain removal / redeposition inhibitor, a brightening agent, a foam inhibitor, a silicone, a hueing agent, an aesthetic dye, a pure perfume, a perfume delivery system, a structure elasticizer, a carrier, a hydrotrope, a processing aid, an anti-aggregation agent, a coating, a formaldehyde scavenger, and / or a pigment.

10. The auxiliary component(s) of the treatment composition according to claim 1 comprises a conditioning active substance.

11. The treatment composition according to claim 1 is in the form of a liquid composition, a granular composition, a hydrocolloid, a single-compartment pouch, a multi-compartment pouch, a soluble sheet, a pastille or bead, a fibrous article, a tablet, a stick, a bar, a flake, a foam or mousse, a non-woven sheet, or a mixture thereof.

12. The beneficial agent precursor compound is present in the treatment composition at a concentration of 0.001 wt% to 30 wt% of the treatment composition, of the treatment composition according to claim 1.

Images